US9228186B2
(en)
|
2002-11-14 |
2016-01-05 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
WO2005089224A2
(en)
|
2004-03-12 |
2005-09-29 |
Alnylam Pharmaceuticals, Inc. |
iRNA AGENTS TARGETING VEGF
|
EP3249052B1
(en)
|
2006-05-11 |
2019-04-10 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the pcsk9 gene
|
US8598333B2
(en)
*
|
2006-05-26 |
2013-12-03 |
Alnylam Pharmaceuticals, Inc. |
SiRNA silencing of genes expressed in cancer
|
AU2009241591A1
(en)
*
|
2008-01-31 |
2009-11-05 |
Alnylam Pharmaceuticals, Inc. |
Optimized methods for delivery of DSRNA targeting the PCSK9 gene
|
CA2716793A1
(en)
*
|
2008-03-05 |
2009-09-11 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of eg5 and vegf genes
|
CA2721333C
(en)
|
2008-04-15 |
2020-12-01 |
Protiva Biotherapeutics, Inc. |
Novel lipid formulations for nucleic acid delivery
|
EP3109321B1
(en)
|
2008-09-25 |
2019-05-01 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene
|
EA020312B1
(ru)
|
2008-10-20 |
2014-10-30 |
Элнилэм Фармасьютикалз, Инк. |
Композиции и способы для ингибирования экспрессии транстиретина
|
KR102042721B1
(ko)
*
|
2008-11-10 |
2019-11-11 |
알닐람 파마슈티칼스 인코포레이티드 |
치료제 운반용 신규 지질 및 조성물
|
EP2373382B1
(en)
|
2008-12-10 |
2017-02-15 |
Alnylam Pharmaceuticals, Inc. |
Gnaq targeted dsrna compositions and methods for inhibiting expression
|
CA2754043A1
(en)
*
|
2009-03-12 |
2010-09-16 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
|
CA2760706C
(en)
*
|
2009-05-05 |
2019-08-06 |
Alnylam Pharmaceuticals, Inc. |
Methods of delivering oligonucleotides to immune cells
|
KR20230098713A
(ko)
*
|
2009-06-10 |
2023-07-04 |
알닐람 파마슈티칼스 인코포레이티드 |
향상된 지질 조성물
|
WO2010147992A1
(en)
|
2009-06-15 |
2010-12-23 |
Alnylam Pharmaceuticals, Inc. |
Methods for increasing efficacy of lipid formulated sirna
|
BRPI1010689A2
(pt)
|
2009-06-15 |
2016-03-15 |
Alnylam Pharmaceuticals Inc |
"dsrna formulado por lipídios direcionados para o gene pcsk9"
|
JP5766188B2
(ja)
|
2009-07-01 |
2015-08-19 |
プロチバ バイオセラピューティクス インコーポレイティッド |
固形腫瘍に治療剤を送達するための脂質製剤
|
EP2810643A3
(en)
|
2009-08-14 |
2015-03-11 |
Alnylam Pharmaceuticals Inc. |
Lipid formulated compositions and mehods for inhibiting expression of a gene from the ebola virus
|
WO2011034798A1
(en)
|
2009-09-15 |
2011-03-24 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
|
US9187746B2
(en)
|
2009-09-22 |
2015-11-17 |
Alnylam Pharmaceuticals, Inc. |
Dual targeting siRNA agents
|
PT3354657T
(pt)
|
2009-09-22 |
2022-05-06 |
Medicago Inc |
Método de preparação de proteínas derivadas de plantas
|
EP2496238A4
(en)
|
2009-11-03 |
2013-10-02 |
Alnylam Pharmaceuticals Inc |
FORMULATED LIPID COMPOSITIONS AND METHODS FOR INHIBITING TRANSTHYRETIN EXPRESSION (TTR)
|
PT3338765T
(pt)
|
2009-12-01 |
2019-03-18 |
Translate Bio Inc |
Derivado de esteróide adequado para a administração de arnm em doenças genéticas humanas
|
WO2011075656A1
(en)
*
|
2009-12-18 |
2011-06-23 |
The University Of British Columbia |
Methods and compositions for delivery of nucleic acids
|
US8846631B2
(en)
|
2010-01-14 |
2014-09-30 |
Regulus Therapeutics Inc. |
MicroRNA compositions and methods
|
CA2799091A1
(en)
|
2010-05-12 |
2011-11-17 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods of use thereof
|
WO2011141704A1
(en)
|
2010-05-12 |
2011-11-17 |
Protiva Biotherapeutics, Inc |
Novel cyclic cationic lipids and methods of use
|
US9006417B2
(en)
|
2010-06-30 |
2015-04-14 |
Protiva Biotherapeutics, Inc. |
Non-liposomal systems for nucleic acid delivery
|
MX2013000164A
(es)
|
2010-07-06 |
2013-03-05 |
Novartis Ag |
Liposomas con lipidos que tienen valor de pka ventajoso para suministro de arn.
|
JP5940064B2
(ja)
|
2010-07-06 |
2016-06-29 |
ノバルティス アーゲー |
低用量のrnaを用いた大型哺乳動物の免疫化
|
EP2590670B1
(en)
|
2010-07-06 |
2017-08-23 |
GlaxoSmithKline Biologicals SA |
Methods of raising an immune response by delivery of rna
|
US20130202652A1
(en)
*
|
2010-07-30 |
2013-08-08 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
US8822663B2
(en)
|
2010-08-06 |
2014-09-02 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
EP3587574B1
(en)
|
2010-08-17 |
2022-03-16 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
|
EP2609106A4
(en)
|
2010-08-26 |
2014-03-19 |
Merck Sharp & Dohme |
RNA INTERFERENCE-MEDIATED INHIBITION OF EXPRESSION OF PHD2 GENE (PROLYL HYDROXYLASE DOMAIN 2) USING SMALL INTERFERING NUCLEIC ACID (PANI)
|
HRP20220695T1
(hr)
|
2010-08-31 |
2022-07-08 |
Glaxosmithkline Biologicals Sa |
Pegilirani liposomi za isporuku rnk kodirane za imunogen
|
US8466122B2
(en)
|
2010-09-17 |
2013-06-18 |
Protiva Biotherapeutics, Inc. |
Trialkyl cationic lipids and methods of use thereof
|
EP3144015B1
(en)
|
2010-09-20 |
2021-06-02 |
Sirna Therapeutics, Inc. |
Low molecular weight cationic lipids for oligonucleotide delivery
|
CA3162352A1
(en)
|
2010-10-01 |
2012-04-05 |
Modernatx, Inc. |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
KR102162111B1
(ko)
|
2010-10-11 |
2020-10-07 |
노파르티스 아게 |
항원 전달 플랫폼
|
JP2013545727A
(ja)
|
2010-10-21 |
2013-12-26 |
メルク・シャープ・アンド・ドーム・コーポレーション |
オリゴヌクレオチド送達用の新規低分子量カチオン性脂質
|
EP2632472B1
(en)
|
2010-10-29 |
2017-12-13 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
|
WO2012061259A2
(en)
|
2010-11-05 |
2012-05-10 |
Merck Sharp & Dohme Corp. |
Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery
|
WO2012075040A2
(en)
|
2010-11-30 |
2012-06-07 |
Shire Human Genetic Therapies, Inc. |
mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
|
TWI620816B
(zh)
|
2011-03-23 |
2018-04-11 |
苜蓿股份有限公司 |
植物衍生蛋白回收方法
|
AU2012236099A1
(en)
|
2011-03-31 |
2013-10-03 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
WO2012151575A2
(en)
*
|
2011-05-05 |
2012-11-08 |
Duke University |
A method of controlling coagulation
|
EP2714971A4
(en)
*
|
2011-05-23 |
2015-01-21 |
Phylogica Ltd |
METHOD FOR DETERMINING, IDENTIFYING AND INSULATING CELL-PENETRATING PEPTIDES
|
BR112013031553A2
(pt)
|
2011-06-08 |
2020-11-10 |
Shire Human Genetic Therapies, Inc. |
composições, mrna que codifica para uma hgla e seu uso, uso de pelo menos uma molécula de mrna e um veículo de transferência e uso de um mrna que codifica para proteína exógena
|
RU2711799C2
(ru)
|
2011-06-21 |
2020-01-22 |
Элнилэм Фармасьютикалз, Инк. |
КОМПОЗИЦИИ иРНК ДЛЯ СХОДНОГО С АНГИОПОЭТИНОМ 3(ANGPTL3) БЕЛКА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
CN103649103A
(zh)
*
|
2011-06-21 |
2014-03-19 |
阿尔尼拉姆医药品有限公司 |
用于抑制载脂蛋白c-iii(apoc3)基因表达的组合物与方法
|
EP3388068A1
(en)
|
2011-06-21 |
2018-10-17 |
Alnylam Pharmaceuticals, Inc. |
Composition and methods for inhibition of expression of protein c (proc) genes
|
EP2729165B1
(en)
|
2011-07-06 |
2017-11-08 |
GlaxoSmithKline Biologicals SA |
Immunogenic combination compositions and uses thereof
|
EP2751270B1
(en)
|
2011-08-29 |
2018-08-22 |
Ionis Pharmaceuticals, Inc. |
Oligomer-conjugate complexes and their use
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
US9428535B2
(en)
|
2011-10-03 |
2016-08-30 |
Moderna Therapeutics, Inc. |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
KR20220045091A
(ko)
|
2011-11-18 |
2022-04-12 |
알닐람 파마슈티칼스 인코포레이티드 |
트랜스티레틴(TTR) 관련 질병을 치료하기 위한 RNAi 제제, 조성 및 그의 사용방법
|
CA2856742A1
(en)
|
2011-12-07 |
2013-06-13 |
Alnylam Pharmaceuticals, Inc. |
Biodegradable lipids for the delivery of active agents
|
US9463247B2
(en)
*
|
2011-12-07 |
2016-10-11 |
Alnylam Pharmaceuticals, Inc. |
Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents
|
EP2791160B1
(en)
|
2011-12-16 |
2022-03-02 |
ModernaTX, Inc. |
Modified mrna compositions
|
US9035039B2
(en)
|
2011-12-22 |
2015-05-19 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing SMAD4
|
EP3988104A1
(en)
|
2012-02-24 |
2022-04-27 |
Arbutus Biopharma Corporation |
Trialkyl cationic lipids and methods of use thereof
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
US9303079B2
(en)
|
2012-04-02 |
2016-04-05 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
AU2013243949A1
(en)
|
2012-04-02 |
2014-10-30 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of biologics and proteins associated with human disease
|
US10501513B2
(en)
*
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides for the production of oncology-related proteins and peptides
|
AU2013243946A1
(en)
*
|
2012-04-02 |
2014-10-30 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of membrane proteins
|
AU2013249548A1
(en)
|
2012-04-19 |
2014-11-06 |
Sirna Therapeutics, Inc. |
Novel diester and triester based low molecular weight, biodegradable cationic lipids for oligonucleotide delivery
|
US9127274B2
(en)
*
|
2012-04-26 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Serpinc1 iRNA compositions and methods of use thereof
|
WO2013163628A2
(en)
|
2012-04-27 |
2013-10-31 |
Duke University |
Genetic correction of mutated genes
|
WO2013170146A1
(en)
|
2012-05-10 |
2013-11-14 |
Uab Research Foundation |
Methods and compositions for modulating mir-204 activity
|
EA201492055A1
(ru)
|
2012-06-08 |
2015-11-30 |
Шир Хьюман Дженетик Терапис, Инк. |
ИНГАЛЯЦИОННАЯ ДОСТАВКА мРНК В НЕЛЕГОЧНЫЕ КЛЕТКИ-МИШЕНИ
|
EP2859102A4
(en)
|
2012-06-08 |
2016-05-11 |
Shire Human Genetic Therapies |
NUCLEASE RESISTANT POLYNUCLEOTIDES AND USES THEREOF
|
US9415109B2
(en)
|
2012-07-06 |
2016-08-16 |
Alnylam Pharmaceuticals, Inc. |
Stable non-aggregating nucleic acid lipid particle formulations
|
EP2885419A4
(en)
|
2012-08-14 |
2016-05-25 |
Moderna Therapeutics Inc |
ENZYMES AND POLYMERASES FOR RNA SYNTHESIS
|
US20140120157A1
(en)
*
|
2012-09-19 |
2014-05-01 |
Georgetown University |
Targeted liposomes
|
LT2922554T
(lt)
|
2012-11-26 |
2022-06-27 |
Modernatx, Inc. |
Terminaliai modifikuota rnr
|
HUE035887T2
(en)
|
2012-12-05 |
2018-05-28 |
Alnylam Pharmaceuticals Inc |
PCSK9 iRNA preparations and methods for their use
|
US9687448B2
(en)
*
|
2012-12-07 |
2017-06-27 |
Alnylam Pharmaceuticals, Inc. |
Nucleic acid lipid particle formulations
|
JP2016504050A
(ja)
|
2013-01-17 |
2016-02-12 |
モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. |
細胞表現型の改変のためのシグナルセンサーポリヌクレオチド
|
CN104254320A
(zh)
*
|
2013-03-06 |
2014-12-31 |
百奥迈科生物技术有限公司 |
脂质体制剂、制备方法及其应用
|
EP2968391A1
(en)
*
|
2013-03-13 |
2016-01-20 |
Moderna Therapeutics, Inc. |
Long-lived polynucleotide molecules
|
EP2971010B1
(en)
|
2013-03-14 |
2020-06-10 |
ModernaTX, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
MX366660B
(es)
|
2013-03-14 |
2019-07-18 |
Alnylam Pharmaceuticals Inc |
Composiciones de arni contra el componente c5 del complemento y métodos para su uso.
|
EP3932947A1
(en)
|
2013-03-14 |
2022-01-05 |
Translate Bio MA, Inc. |
Methods and compositions for delivering mrna coded antibodies
|
IL305374A
(en)
|
2013-03-14 |
2023-10-01 |
Ethris Gmbh |
CFTR mRNA Assemblies and Related Methods and Uses
|
US9957499B2
(en)
|
2013-03-14 |
2018-05-01 |
Translate Bio, Inc. |
Methods for purification of messenger RNA
|
EP2968147A4
(en)
*
|
2013-03-15 |
2017-02-22 |
The Penn State Research Foundation |
Acid stable liposomal compositions
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
US10130649B2
(en)
|
2013-03-15 |
2018-11-20 |
Translate Bio, Inc. |
Synergistic enhancement of the delivery of nucleic acids via blended formulations
|
US10590161B2
(en)
|
2013-03-15 |
2020-03-17 |
Modernatx, Inc. |
Ion exchange purification of mRNA
|
WO2014152031A1
(en)
|
2013-03-15 |
2014-09-25 |
Moderna Therapeutics, Inc. |
Ribonucleic acid purification
|
US10342760B2
(en)
*
|
2013-03-15 |
2019-07-09 |
The University Of British Columbia |
Lipid nanoparticles for transfection and related methods
|
AU2014259759B2
(en)
|
2013-05-01 |
2020-06-18 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods
|
AR096203A1
(es)
|
2013-05-06 |
2015-12-16 |
Alnylam Pharmaceuticals Inc |
Dosificaciones y métodos para administrar moléculas de ácido nucleico formuladas en lípidos
|
KR102234623B1
(ko)
|
2013-05-22 |
2021-04-02 |
알닐람 파마슈티칼스 인코포레이티드 |
Tmprss6 조성물 및 이의 사용 방법
|
UY35582A
(es)
|
2013-05-22 |
2014-10-31 |
Alnylam Pharmaceuticals Inc |
COMPOSICIONES DE ARNi DE SERPINA1 Y SUS MÉTODOS DE USO
|
PL3019619T3
(pl)
|
2013-07-11 |
2022-01-10 |
Modernatx, Inc. |
Kompozycje zawierające syntetyczne polinkleotydy kodujące białka powiązane z crispr i syntetyczne sgrna oraz sposoby ich stosowania
|
US20160151284A1
(en)
|
2013-07-23 |
2016-06-02 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for delivering messenger rna
|
US20160194625A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
US20160194368A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
US10195291B2
(en)
*
|
2013-09-24 |
2019-02-05 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for the manufacture of lipid nanoparticles
|
US10023626B2
(en)
|
2013-09-30 |
2018-07-17 |
Modernatx, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
WO2015051169A2
(en)
|
2013-10-02 |
2015-04-09 |
Moderna Therapeutics, Inc. |
Polynucleotide molecules and uses thereof
|
CA2926218A1
(en)
|
2013-10-03 |
2015-04-09 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
CA2928188A1
(en)
|
2013-10-22 |
2015-04-30 |
Shire Human Genetic Therapies, Inc. |
Mrna therapy for argininosuccinate synthetase deficiency
|
WO2015061461A1
(en)
|
2013-10-22 |
2015-04-30 |
Shire Human Genetic Therapies, Inc. |
Cns delivery of mrna and uses thereof
|
EP3574923A1
(en)
|
2013-10-22 |
2019-12-04 |
Translate Bio, Inc. |
Mrna therapy for phenylketonuria
|
KR102096796B1
(ko)
|
2013-10-22 |
2020-05-27 |
샤이어 휴먼 지네틱 테라피즈 인크. |
메신저 rna의 전달을 위한 지질 제형
|
AU2014348212C1
(en)
|
2013-11-18 |
2018-11-29 |
Arcturus Therapeutics, Inc. |
Ionizable cationic lipid for RNA delivery
|
AU2014351482B2
(en)
|
2013-11-22 |
2020-08-20 |
Mina Therapeutics Limited |
C/EBP alpha short activating RNA compositions and methods of use
|
CA3107872A1
(en)
|
2013-12-12 |
2015-06-18 |
Alnylam Pharmaceuticals, Inc. |
Complement component irna compositions and methods of use thereof
|
JP6389477B2
(ja)
|
2014-01-09 |
2018-09-12 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
カチオン性脂質
|
EP3105331B1
(en)
|
2014-02-11 |
2021-06-23 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk) irna compositions and methods of use thereof
|
EP3110401A4
(en)
|
2014-02-25 |
2017-10-25 |
Merck Sharp & Dohme Corp. |
Lipid nanoparticle vaccine adjuvants and antigen delivery systems
|
EP3981437A1
(en)
|
2014-04-23 |
2022-04-13 |
ModernaTX, Inc. |
Nucleic acid vaccines
|
ES2750661T3
(es)
|
2014-04-25 |
2020-03-26 |
Translate Bio Inc |
Métodos para la purificación de ARN mensajero
|
EP3137476B1
(en)
|
2014-04-28 |
2019-10-09 |
Ionis Pharmaceuticals, Inc. |
Linkage modified oligomeric compounds
|
MX2016014013A
(es)
|
2014-05-01 |
2016-11-15 |
Ionis Pharmaceuticals Inc |
Composiciones y metodos para modular la expresion del receptor de la hormona del crecimiento.
|
RU2701645C2
(ru)
|
2014-05-01 |
2019-09-30 |
Ионис Фармасьютикалз, Инк. |
Композиции и способы модулирования экспрессии фактора комплемента в
|
WO2015168532A2
(en)
|
2014-05-01 |
2015-11-05 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulating pkk expression
|
BR122020024443B1
(pt)
|
2014-05-01 |
2022-02-22 |
Ionis Pharmaceuticals, Inc |
Composto e composição farmacêutica para modulação da expressão de angptl3
|
US20150316566A1
(en)
|
2014-05-02 |
2015-11-05 |
Cerenis Therapeutics Holding Sa |
Hdl therapy markers
|
US10570169B2
(en)
|
2014-05-22 |
2020-02-25 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
SG11201609376SA
(en)
|
2014-05-22 |
2016-12-29 |
Alnylam Pharmaceuticals Inc |
Angiotensinogen (agt) irna compositions and methods of use thereof
|
EP3587409B8
(en)
|
2014-05-30 |
2022-07-13 |
Translate Bio, Inc. |
Biodegradable lipids for delivery of nucleic acids
|
WO2015188194A1
(en)
*
|
2014-06-06 |
2015-12-10 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for enhanced intestinal absorption of conjugated oligomeric compounds
|
CA2952824C
(en)
|
2014-06-24 |
2023-02-21 |
Shire Human Genetic Therapies, Inc. |
Stereochemically enriched compositions for delivery of nucleic acids
|
HUE060907T2
(hu)
|
2014-06-25 |
2023-04-28 |
Acuitas Therapeutics Inc |
Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére
|
EP3164112A1
(en)
|
2014-07-02 |
2017-05-10 |
Shire Human Genetic Therapies, Inc. |
Encapsulation of messenger rna
|
CA2955250A1
(en)
|
2014-07-16 |
2016-01-21 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
WO2016014846A1
(en)
|
2014-07-23 |
2016-01-28 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of intrabodies
|
KR20220087571A
(ko)
|
2014-08-29 |
2022-06-24 |
알닐람 파마슈티칼스 인코포레이티드 |
트랜스타이레틴(ttr) 매개 아밀로이드증의 치료 방법
|
EP3191591A1
(en)
|
2014-09-12 |
2017-07-19 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting complement component c5 and methods of use thereof
|
JOP20200115A1
(ar)
|
2014-10-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
|
WO2016061487A1
(en)
|
2014-10-17 |
2016-04-21 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
|
WO2016065349A2
(en)
|
2014-10-24 |
2016-04-28 |
University Of Maryland, Baltimore |
Short non-coding protein regulatory rnas (sprrnas) and methods of use
|
EP3212794B1
(en)
*
|
2014-10-30 |
2021-04-07 |
Genzyme Corporation |
Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
|
JOP20200092A1
(ar)
|
2014-11-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
|
JP2017535552A
(ja)
|
2014-11-17 |
2017-11-30 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法
|
ES2861597T3
(es)
|
2014-12-05 |
2021-10-06 |
Translate Bio Inc |
Terapia de ARN mensajero para el tratamiento de enfermedad articular
|
JP2018504380A
(ja)
*
|
2014-12-18 |
2018-02-15 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
Reversir(商標)化合物
|
JP6592458B2
(ja)
|
2014-12-26 |
2019-10-16 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
カチオン性脂質
|
JP2018510621A
(ja)
|
2015-02-13 |
2018-04-19 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
パタチン様ホスホリパーゼドメイン含有3(PNPLA3)iRNA組成物およびその使用方法
|
EP3270894B1
(en)
|
2015-03-19 |
2021-02-24 |
Translate Bio, Inc. |
Mrna therapy for pompe disease
|
WO2016164746A1
(en)
|
2015-04-08 |
2016-10-13 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
TWI723986B
(zh)
|
2015-04-13 |
2021-04-11 |
美商阿尼拉製藥公司 |
類血管生成素3(ANGPTL3)iRNA組成物及其用途方法
|
US10660973B2
(en)
|
2015-04-28 |
2020-05-26 |
Duke University |
Thrombus imaging aptamers and methods of using same
|
CN108271386B
(zh)
|
2015-05-06 |
2022-07-15 |
阿尔尼拉姆医药品有限公司 |
因子XII(哈格曼因子)(F12)、激肽释放酶B、血浆(夫列契因子)1(KLKB1)和激肽原1(KNG1)iRNA组合物及其使用方法
|
EP3307316A1
(en)
|
2015-06-12 |
2018-04-18 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions and methods of use thereof
|
EP3310918B1
(en)
|
2015-06-18 |
2020-08-05 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
|
WO2016209862A1
(en)
|
2015-06-23 |
2016-12-29 |
Alnylam Pharmaceuticals, Inc. |
Glucokinase (gck) irna compositions and methods of use thereof
|
WO2017004143A1
(en)
|
2015-06-29 |
2017-01-05 |
Acuitas Therapeutics Inc. |
Lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
US10494632B2
(en)
|
2015-07-10 |
2019-12-03 |
Alnylam Pharmaceuticals, Inc. |
Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
|
CN109477106B
(zh)
|
2015-07-10 |
2022-10-04 |
Ionis制药公司 |
二酰基甘油酰基转移酶2(dgat2)的调节剂
|
PL3329002T3
(pl)
|
2015-07-31 |
2021-04-19 |
Alnylam Pharmaceuticals, Inc. |
Kompozycje irna transtyretyny (ttr) i sposoby ich zastosowania do leczenia lub zapobiegania chorobom związanym z ttr
|
EP3328439B1
(en)
|
2015-07-31 |
2020-04-08 |
Arcturus Therapeutics, Inc. |
Multiligand agent for drug delivery
|
WO2017031232A1
(en)
|
2015-08-17 |
2017-02-23 |
Modernatx, Inc. |
Methods for preparing particles and related compositions
|
PE20181131A1
(es)
|
2015-09-02 |
2018-07-17 |
Alnylam Pharmaceuticals Inc |
COMPOSICIONES DE ARNi PARA LIGANDO 1 DE MUERTE CELULAR PROGRAMADA 1 (PD-L1) Y METODOS DE USO DE LAS MISMAS
|
WO2017048620A1
(en)
|
2015-09-14 |
2017-03-23 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof
|
EP3736261B1
(en)
|
2015-09-17 |
2023-10-11 |
ModernaTX, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
US20180273577A1
(en)
|
2015-09-24 |
2018-09-27 |
Ionis Pharmaceuticals, Inc. |
Modulators of kras expression
|
KR20180073584A
(ko)
|
2015-10-02 |
2018-07-02 |
로슈 이노베이션 센터 코펜하겐 에이/에스 |
올리고뉴클레오타이드 접합 방법
|
AU2016336344A1
(en)
|
2015-10-05 |
2018-04-19 |
Modernatx, Inc. |
Methods for therapeutic administration of messenger ribonucleic acid drugs
|
EP4089175A1
(en)
|
2015-10-13 |
2022-11-16 |
Duke University |
Genome engineering with type i crispr systems in eukaryotic cells
|
EP3362555B1
(en)
|
2015-10-14 |
2021-01-13 |
Translate Bio, Inc. |
Modification of rna-related enzymes for enhanced production
|
SI3718565T1
(sl)
|
2015-10-22 |
2022-08-31 |
Modernatx, Inc. |
Cepiva za respiratorni virus
|
CA3003055C
(en)
|
2015-10-28 |
2023-08-01 |
Acuitas Therapeutics, Inc. |
Lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
EP3371201A4
(en)
|
2015-11-06 |
2019-09-18 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds for use in therapy
|
MX2018005277A
(es)
|
2015-11-06 |
2018-08-01 |
Ionis Pharmaceuticals Inc |
Modular la expresion de apolipoproteina (a).
|
WO2017087846A1
(en)
|
2015-11-18 |
2017-05-26 |
Provivi, Inc. |
Microorganisms for the production of insect pheromones and related compounds
|
US11091759B2
(en)
|
2015-12-07 |
2021-08-17 |
Genzyme Corporation |
Methods and compositions for treating a Serpinc1-associated disorder
|
WO2017100542A1
(en)
|
2015-12-10 |
2017-06-15 |
Alnylam Pharmaceuticals, Inc. |
Sterol regulatory element binding protein (srebp) chaperone (scap) irna compositions and methods of use thereof
|
WO2017099823A1
(en)
|
2015-12-10 |
2017-06-15 |
Modernatx, Inc. |
Compositions and methods for delivery of therapeutic agents
|
HUE057877T2
(hu)
|
2015-12-22 |
2022-06-28 |
Modernatx Inc |
Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására
|
LT3394093T
(lt)
|
2015-12-23 |
2022-04-25 |
Modernatx, Inc. |
Ox40 ligandus koduojančių polinukleotidų naudojimo būdai
|
MA43587A
(fr)
|
2016-01-10 |
2018-11-14 |
Modernatx Inc |
Arnm thérapeutiques codant pour des anticorps anti-ctla-4
|
WO2017127750A1
(en)
|
2016-01-22 |
2017-07-27 |
Modernatx, Inc. |
Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
|
ES2898337T3
(es)
|
2016-03-03 |
2022-03-07 |
Univ Massachusetts |
ADN dúplex lineal de extremos cerrados para la transferencia de genes no víricos
|
KR20230048446A
(ko)
|
2016-03-07 |
2023-04-11 |
애로우헤드 파마슈티컬스 인코포레이티드 |
치료용 화합물을 위한 표적화 리간드
|
AU2017248189B2
(en)
|
2016-04-08 |
2021-04-29 |
Translate Bio, Inc. |
Multimeric coding nucleic acid and uses thereof
|
WO2017180917A2
(en)
|
2016-04-13 |
2017-10-19 |
Modernatx, Inc. |
Lipid compositions and their uses for intratumoral polynucleotide delivery
|
MA45295A
(fr)
|
2016-04-19 |
2019-02-27 |
Alnylam Pharmaceuticals Inc |
Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser
|
JP7066632B2
(ja)
*
|
2016-05-09 |
2022-05-13 |
アストラゼネカ・アクチエボラーグ |
親油性抗炎症剤を含む脂質ナノ粒子およびその使用方法
|
US20190298657A1
(en)
|
2016-05-18 |
2019-10-03 |
Modernatx, Inc. |
Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency
|
CA3024507A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polynucleotides encoding .alpha.-galactosidase a for the treatment of fabry disease
|
WO2017201340A2
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polynucleotides encoding relaxin
|
EP4186518A1
(en)
|
2016-05-18 |
2023-05-31 |
ModernaTX, Inc. |
Polynucleotides encoding interleukin-12 (il12) and uses thereof
|
EP3458081A1
(en)
|
2016-05-18 |
2019-03-27 |
Modernatx, Inc. |
Polynucleotides encoding citrin for the treatment of citrullinemia type 2
|
CN109890832B
(zh)
*
|
2016-06-06 |
2022-08-12 |
普罗维维股份有限公司 |
脂肪醇和脂肪醛的半生物合成产生
|
EP3469083A1
(en)
|
2016-06-10 |
2019-04-17 |
Alnylam Pharmaceuticals, Inc. |
COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
|
CN109312313A
(zh)
|
2016-06-13 |
2019-02-05 |
川斯勒佰尔公司 |
用于治疗鸟氨酸转氨甲酰酶缺乏症的信使rna疗法
|
US10501416B2
(en)
|
2016-06-24 |
2019-12-10 |
Eisai R&D Management Co., Ltd. |
Cationic lipid
|
US11191849B2
(en)
|
2016-06-30 |
2021-12-07 |
Arbutus Biopharma Corporation |
Compositions and methods for delivering messenger RNA
|
JP7197463B2
(ja)
|
2016-07-15 |
2022-12-27 |
アイオーニス ファーマシューティカルズ, インコーポレーテッド |
Smn2の調節のための化合物及び方法
|
GB201614120D0
(en)
*
|
2016-08-18 |
2016-10-05 |
Univ Of Kwazulu-Natal |
pH-responsive lipids
|
US20190185859A1
(en)
|
2016-08-19 |
2019-06-20 |
Curevac Ag |
Rna for cancer therapy
|
WO2018041921A1
(en)
|
2016-08-31 |
2018-03-08 |
Curevac Ag |
Mixing device for the production of a liquid nucleic acid composition
|
KR20230115344A
(ko)
|
2016-09-02 |
2023-08-02 |
애로우헤드 파마슈티컬스 인코포레이티드 |
표적화 리간드
|
EP3506909B1
(en)
|
2016-09-02 |
2022-06-29 |
Dicerna Pharmaceuticals, Inc. |
4'-phosphate analogs and oligonucleotides comprising the same
|
JP7217700B2
(ja)
|
2016-09-13 |
2023-02-03 |
アラーガン、インコーポレイテッド |
安定化非タンパク質クロストリジウム毒素組成物
|
JP2019528739A
(ja)
|
2016-09-16 |
2019-10-17 |
デューク ユニバーシティ |
フォン・ビルブラント因子(vwf)標的薬剤およびそれを用いる方法
|
EP3519578B1
(en)
|
2016-10-03 |
2021-12-22 |
Precision Nanosystems Inc |
Compositions for transfecting resistant cell types
|
KR20190065341A
(ko)
|
2016-10-06 |
2019-06-11 |
아이오니스 파마수티컬즈, 인코포레이티드 |
올리고머 화합물들의 접합 방법
|
AU2017347837A1
(en)
|
2016-10-26 |
2019-06-06 |
Modernatx, Inc. |
Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
|
WO2018089540A1
(en)
|
2016-11-08 |
2018-05-17 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
TWI788312B
(zh)
|
2016-11-23 |
2023-01-01 |
美商阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法
|
JP2020501545A
(ja)
|
2016-12-08 |
2020-01-23 |
キュアバック アーゲー |
肝疾患の処置または予防のためのrna
|
WO2018104540A1
(en)
|
2016-12-08 |
2018-06-14 |
Curevac Ag |
Rnas for wound healing
|
KR20230166146A
(ko)
|
2016-12-16 |
2023-12-06 |
알닐람 파마슈티칼스 인코포레이티드 |
트랜스티레틴(TTR) iRNA 조성물을 사용하여 TTR-관련 질병을 치료하거나 예방하는 방법
|
US10383952B2
(en)
|
2016-12-21 |
2019-08-20 |
Arcturus Therapeutics, Inc. |
Ionizable cationic lipid for RNA delivery
|
US10526284B2
(en)
|
2016-12-21 |
2020-01-07 |
Arcturus Therapeutics, Inc. |
Ionizable cationic lipid for RNA delivery
|
US11464847B2
(en)
|
2016-12-23 |
2022-10-11 |
Curevac Ag |
Lassa virus vaccine
|
EP3558355A2
(en)
|
2016-12-23 |
2019-10-30 |
CureVac AG |
Henipavirus vaccine
|
WO2018115527A2
(en)
|
2016-12-23 |
2018-06-28 |
Curevac Ag |
Mers coronavirus vaccine
|
US20190351039A1
(en)
|
2017-02-01 |
2019-11-21 |
Modernatx, Inc. |
Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
|
WO2018146506A1
(en)
*
|
2017-02-10 |
2018-08-16 |
Universitat Politècnica De València |
Therapeutic derivatives
|
EP3585417B1
(en)
|
2017-02-27 |
2023-02-22 |
Translate Bio, Inc. |
Method of making a codon-optimized cftr mrna
|
US11969506B2
(en)
|
2017-03-15 |
2024-04-30 |
Modernatx, Inc. |
Lipid nanoparticle formulation
|
ES2940259T3
(es)
|
2017-03-15 |
2023-05-04 |
Modernatx Inc |
Compuesto y composiciones para la administración intracelular de agentes terapéuticos
|
ES2911186T3
(es)
*
|
2017-03-15 |
2022-05-18 |
Modernatx Inc |
Formas cristalinas de aminolípidos
|
CA3050614A1
(en)
|
2017-03-17 |
2018-09-20 |
Curevac Ag |
Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy
|
JOP20190215A1
(ar)
|
2017-03-24 |
2019-09-19 |
Ionis Pharmaceuticals Inc |
مُعدّلات التعبير الوراثي عن pcsk9
|
CN110914433A
(zh)
|
2017-03-24 |
2020-03-24 |
库尔维科公司 |
编码crispr相关蛋白质的核酸及其用途
|
EP3607074A4
(en)
|
2017-04-05 |
2021-07-07 |
Modernatx, Inc. |
REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS THERAPEUTIC PROTEINS, FOR EXAMPLE SUBCUTANEOUSLY
|
WO2018191657A1
(en)
|
2017-04-13 |
2018-10-18 |
Acuitas Therapeutics, Inc. |
Lipids for delivery of active agents
|
MA50278A
(fr)
|
2017-04-18 |
2020-02-26 |
Alnylam Pharmaceuticals Inc |
Méthodes pour le traitement de sujets atteints d'une infection par le virus de l'hépatite b (vhb)
|
AU2018256877B2
(en)
|
2017-04-28 |
2022-06-02 |
Acuitas Therapeutics, Inc. |
Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
IL270631B2
(en)
|
2017-05-16 |
2024-03-01 |
Translate Bio Inc |
Treatment of cystic fibrosis through the administration of mRNA with an optimal codon encoding ctfr
|
AR112543A1
(es)
|
2017-05-17 |
2019-11-13 |
Provivi Inc |
Microorganismos para la producción de feromonas de insectos y compuestos relacionados
|
EP3625363A1
(en)
|
2017-05-17 |
2020-03-25 |
CureVac Real Estate GmbH |
Method for determining at least one quality parameter of an rna sample
|
WO2018213789A1
(en)
|
2017-05-18 |
2018-11-22 |
Modernatx, Inc. |
Modified messenger rna comprising functional rna elements
|
JP7285220B2
(ja)
|
2017-05-18 |
2023-06-01 |
モデルナティエックス インコーポレイテッド |
連結したインターロイキン-12(il12)ポリペプチドをコードするポリヌクレオチドを含む脂質ナノ粒子
|
EP3630985A4
(en)
|
2017-05-31 |
2021-06-09 |
Arcturus Therapeutics, Inc. |
SYNTHESIS AND STRUCTURE OF HIGH POWER RNA-BASED THERAPEUTIC AGENTS
|
BR112019025224A2
(pt)
|
2017-05-31 |
2020-12-08 |
Ultragenyx Pharmaceutical Inc. |
Terapêutica para doença de armazenamento de glicogênio tipo iii
|
WO2018222925A1
(en)
|
2017-05-31 |
2018-12-06 |
Ultragenyx Pharmaceutical Inc. |
Therapeutics for phenylketonuria
|
WO2018226854A2
(en)
|
2017-06-06 |
2018-12-13 |
Wayne State University |
Antifouling polymer coatings and reverse coating method
|
CN109030429B
(zh)
*
|
2017-06-09 |
2022-06-21 |
南京大学 |
一种可对活细胞内microRNA21进行原位成像的纳米放大自参比探针
|
EP3638292A1
(en)
|
2017-06-14 |
2020-04-22 |
ModernaTX, Inc. |
Polynucleotides encoding coagulation factor viii
|
WO2018231990A2
(en)
|
2017-06-14 |
2018-12-20 |
Modernatx, Inc. |
Polynucleotides encoding methylmalonyl-coa mutase
|
US11786607B2
(en)
|
2017-06-15 |
2023-10-17 |
Modernatx, Inc. |
RNA formulations
|
WO2018236849A1
(en)
|
2017-06-19 |
2018-12-27 |
Translate Bio, Inc. |
MESSENGER RNA THERAPY FOR THE TREATMENT OF FRIEDREICH ATAXIA
|
WO2019008001A1
(en)
|
2017-07-04 |
2019-01-10 |
Curevac Ag |
NEW NUCLEIC ACID MOLECULES
|
EP3652317A1
(en)
|
2017-07-13 |
2020-05-20 |
Alnylam Pharmaceuticals, Inc. |
Lactate dehydrogenase a (ldha) irna compositions and methods of use thereof
|
JP7355731B2
(ja)
|
2017-08-16 |
2023-10-03 |
アクイタス セラピューティクス インコーポレイテッド |
脂質ナノ粒子製剤における使用のための脂質
|
WO2019036028A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
|
US11524932B2
(en)
|
2017-08-17 |
2022-12-13 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
MA50751A
(fr)
|
2017-08-18 |
2020-06-24 |
Modernatx Inc |
Vaccins à base d'arnm efficaces
|
WO2019038332A1
(en)
|
2017-08-22 |
2019-02-28 |
Curevac Ag |
VACCINE AGAINST BUNYAVIRUS
|
WO2019046809A1
(en)
|
2017-08-31 |
2019-03-07 |
Modernatx, Inc. |
METHODS OF MANUFACTURING LIPID NANOPARTICLES
|
EP3679138B1
(en)
|
2017-09-08 |
2023-03-22 |
MiNA Therapeutics Limited |
Hnf4a sarna compositions and methods of use
|
US20200208152A1
(en)
|
2017-09-08 |
2020-07-02 |
Mina Therapeutics Limited |
Stabilized sarna compositions and methods of use
|
KR20200089656A
(ko)
|
2017-09-19 |
2020-07-27 |
알닐람 파마슈티칼스 인코포레이티드 |
트랜스타이레틴(ttr) 매개 아밀로이드증을 치료하기 위한 조성물 및 방법
|
JP2021501572A
(ja)
|
2017-10-19 |
2021-01-21 |
キュアバック アーゲー |
新規な人工核酸分子
|
SG11202002940QA
(en)
|
2017-11-01 |
2020-04-29 |
Alnylam Pharmaceuticals Inc |
Complement component c3 irna compositions and methods of use thereof
|
EP3707271A1
(en)
|
2017-11-08 |
2020-09-16 |
CureVac AG |
Rna sequence adaptation
|
US20210236644A1
(en)
|
2017-11-10 |
2021-08-05 |
Cocoon Biotech Inc. |
Ocular applications of silk-based products
|
EP3710587A1
(en)
|
2017-11-16 |
2020-09-23 |
Alnylam Pharmaceuticals, Inc. |
Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
|
WO2019100039A1
(en)
|
2017-11-20 |
2019-05-23 |
Alnylam Pharmaceuticals, Inc. |
Serum amyloid p component (apcs) irna compositions and methods of use thereof
|
WO2019104198A2
(en)
*
|
2017-11-22 |
2019-05-31 |
Beckman Coulter, Inc. |
Diluent preparation modules and units
|
MA50801A
(fr)
|
2017-11-22 |
2020-09-30 |
Modernatx Inc |
Polynucléotides codant pour la phénylalanine hydroxylase pour le traitement de la phénylcétonurie
|
MA50802A
(fr)
|
2017-11-22 |
2020-09-30 |
Modernatx Inc |
Polynucléotides codant pour des sous-unités alpha et bêta de propionyl-coa carboxylase pour le traitement de l'acidémie propionique
|
EP3714048A1
(en)
|
2017-11-22 |
2020-09-30 |
Modernatx, Inc. |
Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders
|
EP3723796A1
(en)
|
2017-12-13 |
2020-10-21 |
CureVac AG |
Flavivirus vaccine
|
US20200308588A1
(en)
|
2017-12-18 |
2020-10-01 |
Alnylam Pharmaceuticals, Inc. |
High mobility group box-1 (hmgb1) irna compositions and methods of use thereof
|
AU2018392716A1
(en)
|
2017-12-20 |
2020-06-18 |
Translate Bio, Inc. |
Improved composition and methods for treatment of ornithine transcarbamylase deficiency
|
EP3733647B1
(en)
|
2017-12-27 |
2022-06-15 |
Eisai R&D Management Co., Ltd. |
Cationic lipid
|
WO2019136241A1
(en)
|
2018-01-05 |
2019-07-11 |
Modernatx, Inc. |
Polynucleotides encoding anti-chikungunya virus antibodies
|
PE20211242A1
(es)
|
2018-01-15 |
2021-07-09 |
Ionis Pharmaceuticals Inc |
Moduladores de la expresion dnm2
|
EP3746052A1
(en)
|
2018-01-30 |
2020-12-09 |
Modernatx, Inc. |
Compositions and methods for delivery of agents to immune cells
|
EP3752612A4
(en)
|
2018-02-12 |
2021-11-10 |
Ionis Pharmaceuticals, Inc. |
MODIFIED COMPOUNDS AND USES THEREOF
|
WO2019193183A2
(en)
|
2018-04-05 |
2019-10-10 |
Curevac Ag |
Novel yellow fever nucleic acid molecules for vaccination
|
JP2021521141A
(ja)
*
|
2018-04-09 |
2021-08-26 |
オージェネシス インコーポレイテッド |
バイオキソーム粒子、レドキソーム、それらの作製方法、及びそれらを含む組成物
|
US20210163928A1
(en)
|
2018-04-11 |
2021-06-03 |
Modernatx, Inc. |
Messenger rna comprising functional rna elements
|
WO2019197845A1
(en)
|
2018-04-12 |
2019-10-17 |
Mina Therapeutics Limited |
Sirt1-sarna compositions and methods of use
|
MX2020010941A
(es)
|
2018-04-17 |
2021-01-29 |
Curevac Ag |
Moleculas y composiciones novedosas de arn de vsr para vacunacion.
|
JOP20200280A1
(ar)
|
2018-05-09 |
2020-11-05 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير الوراثي عن fxi
|
EP3790607B1
(en)
|
2018-05-11 |
2023-12-27 |
Lupagen, Inc. |
Systems for closed loop, real-time modifications of patient cells
|
TW202016304A
(zh)
|
2018-05-14 |
2020-05-01 |
美商阿尼拉製藥公司 |
血管收縮素原(AGT)iRNA組成物及其使用方法
|
EP3796893A1
(en)
|
2018-05-23 |
2021-03-31 |
Modernatx, Inc. |
Delivery of dna
|
CN112437767B
(zh)
|
2018-05-24 |
2023-10-27 |
川斯勒佰尔公司 |
硫酯阳离子脂质
|
CN112533909A
(zh)
|
2018-05-30 |
2021-03-19 |
川斯勒佰尔公司 |
维生素阳离子脂质
|
CN112672761A
(zh)
|
2018-05-30 |
2021-04-16 |
川斯勒佰尔公司 |
磷酸酯阳离子脂质
|
AU2019277361A1
(en)
|
2018-05-30 |
2020-12-17 |
Translate Bio, Inc. |
Messenger RNA vaccines and uses thereof
|
EP3802558A1
(en)
|
2018-05-30 |
2021-04-14 |
Translate Bio, Inc. |
Cationic lipids comprising a steroidal moiety
|
KR102591743B1
(ko)
|
2018-06-08 |
2023-10-19 |
후지필름 가부시키가이샤 |
화합물 또는 그 염 및 지질 입자
|
US20210260178A1
(en)
|
2018-06-27 |
2021-08-26 |
Curevac Ag |
Novel lassa virus rna molecules and compositions for vaccination
|
EP3813798A1
(en)
|
2018-06-28 |
2021-05-05 |
AstraZeneca AB |
Exosome extracellular vesicles and methods of use
|
KR20210056331A
(ko)
|
2018-07-23 |
2021-05-18 |
트랜슬레이트 바이오 인코포레이티드 |
전령 rna의 건조 분말 제형
|
US20220184185A1
(en)
|
2018-07-25 |
2022-06-16 |
Modernatx, Inc. |
Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
|
EP3833397A4
(en)
|
2018-08-08 |
2023-06-14 |
Arcturus Therapeutics, Inc. |
COMPOSITIONS AND AGENTS AGAINST NON-ALCOHOLIC STEATOHEPATITIS
|
JP2021534101A
(ja)
|
2018-08-09 |
2021-12-09 |
ヴェルソー セラピューティクス, インコーポレイテッド |
Ccr2及びcsf1rを標的とするためのオリゴヌクレオチド組成物ならびにその使用
|
US20210170005A1
(en)
|
2018-08-15 |
2021-06-10 |
University Of Florida Research Foundation, Inc. |
Methods of sensitizing tumors to treatment with immune checkpoint inhibitors
|
US11174500B2
(en)
|
2018-08-24 |
2021-11-16 |
Translate Bio, Inc. |
Methods for purification of messenger RNA
|
AU2019333042A1
(en)
|
2018-08-29 |
2021-03-04 |
Translate Bio, Inc. |
Improved process of preparing mRNA-loaded lipid nanoparticles
|
MA53545A
(fr)
|
2018-09-02 |
2021-07-14 |
Modernatx Inc |
Polynucléotides codant pour l'acyl-coa déshydrogénase à très longue chaîne pour le traitement de l'insuffisance en acyl-coa déshydrogénase à très longue chaîne
|
US20220054610A1
(en)
|
2018-09-12 |
2022-02-24 |
University Of Florida Research Foundation, Inc. |
Slow-cycling cell-rna based nanoparticle vaccine to treat cancer
|
US20220243182A1
(en)
|
2018-09-13 |
2022-08-04 |
Modernatx, Inc. |
Polynucleotides encoding branched-chain alpha-ketoacid dehydrogenase complex e1-alpha, e1-beta, and e2 subunits for the treatment of maple syrup urine disease
|
US20230009009A1
(en)
|
2018-09-13 |
2023-01-12 |
Modernatx, Inc. |
Polynucleotides encoding glucose-6-phosphatase for the treatment of glycogen storage disease
|
US20230081530A1
(en)
|
2018-09-14 |
2023-03-16 |
Modernatx, Inc. |
Methods and compositions for treating cancer using mrna therapeutics
|
EP3849617A1
(en)
|
2018-09-14 |
2021-07-21 |
Translate Bio, Inc. |
Composition and methods for treatment of methylmalonic acidemia
|
CA3112398A1
(en)
|
2018-09-14 |
2020-03-19 |
Modernatx, Inc. |
Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
|
CA3105385A1
(en)
|
2018-09-18 |
2020-03-26 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk) irna compositions and methods of use thereof
|
TW202023573A
(zh)
|
2018-09-19 |
2020-07-01 |
美商Ionis製藥公司 |
Pnpla3表現之調節劑
|
JP2022501367A
(ja)
|
2018-09-20 |
2022-01-06 |
モデルナティエックス インコーポレイテッドModernaTX, Inc. |
脂質ナノ粒子の調製及びその投与方法
|
WO2020069169A1
(en)
|
2018-09-27 |
2020-04-02 |
Modernatx, Inc. |
Polynucleotides encoding arginase 1 for the treatment of arginase deficiency
|
DK3860561T3
(da)
*
|
2018-10-01 |
2023-08-07 |
Alnylam Pharmaceuticals Inc |
Bionedbrydelige lipider til levering af aktive stoffer
|
PL3864163T3
(pl)
|
2018-10-09 |
2024-05-20 |
The University Of British Columbia |
Kompozycje i układy zawierające pęcherzyki zdolne do transfekcji wolne od rozpuszczalników organicznych i detergentów oraz związane z nimi sposoby postępowania
|
KR20210090634A
(ko)
|
2018-10-19 |
2021-07-20 |
트랜슬레이트 바이오 인코포레이티드 |
전령 rna의 무펌프 캡슐화
|
US10913951B2
(en)
|
2018-10-31 |
2021-02-09 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
|
WO2020097409A2
(en)
|
2018-11-08 |
2020-05-14 |
Modernatx, Inc. |
Use of mrna encoding ox40l to treat cancer in human patients
|
KR20210102248A
(ko)
|
2018-11-09 |
2021-08-19 |
트랜슬레이트 바이오 인코포레이티드 |
에스테르, 티오에스테르, 이황화물, 및 무수물 모이어티가 삽입된 2,5-디옥소피페라진
|
US20220071905A1
(en)
|
2018-11-09 |
2022-03-10 |
Translate Bio, Inc. |
Peg lipidoid compounds
|
US20220016265A1
(en)
|
2018-11-09 |
2022-01-20 |
Translate Bio, Inc. |
Messenger rna therapy for treatment of ocular diseases
|
AU2019377525A1
(en)
|
2018-11-09 |
2021-05-27 |
Translate Bio, Inc. |
Multi-PEG lipid compounds
|
WO2020102172A2
(en)
|
2018-11-12 |
2020-05-22 |
Translate Bio, Inc. |
Methods for inducing immune tolerance
|
AU2019383413A1
(en)
|
2018-11-21 |
2021-05-27 |
Translate Bio, Inc. |
Cationic lipid compounds and compositions thereof for use in the delivery of messenger RNA
|
CA3121191A1
(en)
|
2018-11-28 |
2020-06-04 |
Crispr Therapeutics Ag |
Optimized mrna encoding cas9 for use in lnps
|
ES2960692T3
(es)
|
2018-12-06 |
2024-03-06 |
Arcturus Therapeutics Inc |
Composiciones y métodos para el tratamiento de la deficiencia de ornitina transcarbamilasa
|
TW202039534A
(zh)
|
2018-12-14 |
2020-11-01 |
美商美國禮來大藥廠 |
KRAS變體mRNA分子
|
EP3898977A1
(en)
|
2018-12-20 |
2021-10-27 |
Praxis Precision Medicines, Inc. |
Compositions and methods for the treatment of kcnt1 related disorders
|
BR112021009422A2
(pt)
|
2018-12-21 |
2021-10-26 |
Curevac Ag |
Rna para vacinas contra malária
|
US20220087935A1
(en)
|
2019-01-07 |
2022-03-24 |
Translate Bio, Inc. |
Composition and Methods for Treatment of Primary Ciliary Dyskinesia
|
JP2022517783A
(ja)
|
2019-01-11 |
2022-03-10 |
アクイタス セラピューティクス インコーポレイテッド |
活性剤の脂質ナノ粒子送達のための脂質
|
WO2020160430A1
(en)
|
2019-01-31 |
2020-08-06 |
Modernatx, Inc. |
Vortex mixers and associated methods, systems, and apparatuses thereof
|
JP2022519557A
(ja)
|
2019-01-31 |
2022-03-24 |
モデルナティエックス インコーポレイテッド |
脂質ナノ粒子の調製方法
|
EP3920950A1
(en)
|
2019-02-08 |
2021-12-15 |
CureVac AG |
Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
|
MX2021011928A
(es)
|
2019-03-29 |
2022-01-04 |
Dicerna Pharmaceuticals Inc |
Composiciones y metodos para el tratamiento de enfermedades o trastornos asociados con kras.
|
WO2020206231A1
(en)
|
2019-04-05 |
2020-10-08 |
Precision Biosciences, Inc. |
Methods of preparing populations of genetically-modified immune cells
|
US20220211740A1
(en)
|
2019-04-12 |
2022-07-07 |
Mina Therapeutics Limited |
Sirt1-sarna compositions and methods of use
|
WO2020214946A1
(en)
|
2019-04-18 |
2020-10-22 |
Translate Bio, Inc. |
Cystine cationic lipids
|
WO2020219427A1
(en)
|
2019-04-22 |
2020-10-29 |
Translate Bio, Inc. |
Thioester cationic lipids
|
US20220218808A1
(en)
|
2019-05-02 |
2022-07-14 |
University Of Florida Research Foundation, Inc. |
Compositions for treatment of diffuse intrinsic pontine glioma
|
US20220257724A1
(en)
|
2019-05-03 |
2022-08-18 |
Translate Bio, Inc. |
Di-thioester cationic lipids
|
EP3963072A1
(en)
|
2019-05-03 |
2022-03-09 |
Dicerna Pharmaceuticals, Inc. |
Double-stranded nucleic acid inhibitor molecules with shortened sense strands
|
MA55896A
(fr)
|
2019-05-07 |
2022-03-16 |
Modernatx Inc |
Polynucléotides servant à perturber l'activité de cellule immunitaire et procédés pour les utiliser
|
MA55887A
(fr)
|
2019-05-07 |
2022-03-16 |
Modernatx Inc |
Microarn de cellules immunitaires exprimés de manière différentielle pour la régulation de l'expression de protéines
|
EP3965806A1
(en)
|
2019-05-08 |
2022-03-16 |
Modernatx, Inc. |
Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
|
EP3965797A1
(en)
|
2019-05-08 |
2022-03-16 |
AstraZeneca AB |
Compositions for skin and wounds and methods of use thereof
|
EP3972653A1
(en)
|
2019-05-22 |
2022-03-30 |
Massachusetts Institute of Technology |
Circular rna compositions and methods
|
EP3976593A1
(en)
|
2019-05-31 |
2022-04-06 |
Translate Bio, Inc. |
Macrocyclic lipids
|
WO2020247594A1
(en)
|
2019-06-04 |
2020-12-10 |
Cocoon Biotech Inc. |
Silk-based products, formulations, and methods of use
|
CN113924128A
(zh)
*
|
2019-06-07 |
2022-01-11 |
富士胶片株式会社 |
脂质组合物
|
EP3986452A1
(en)
|
2019-06-18 |
2022-04-27 |
CureVac AG |
Rotavirus mrna vaccine
|
US20230092238A1
(en)
|
2019-06-21 |
2023-03-23 |
Translate Bio, Inc. |
Tricine and Citric Acid Lipids
|
WO2020257611A1
(en)
|
2019-06-21 |
2020-12-24 |
Translate Bio, Inc. |
Cationic lipids comprising an hydroxy moiety
|
US20220387628A1
(en)
|
2019-06-24 |
2022-12-08 |
Modernatx, Inc. |
Messenger rna comprising functional rna elements and uses thereof
|
US20220251577A1
(en)
|
2019-06-24 |
2022-08-11 |
Modernatx, Inc. |
Endonuclease-resistant messenger rna and uses thereof
|
CN114390921A
(zh)
|
2019-07-08 |
2022-04-22 |
川斯勒佰尔公司 |
改善的负载mrna的脂质纳米颗粒和其制备方法
|
JP2022541445A
(ja)
|
2019-07-18 |
2022-09-26 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
造血の完全なアブレーションを誘導するための方法
|
JP2022542839A
(ja)
|
2019-07-19 |
2022-10-07 |
フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー |
リコンビナーゼ組成物及び使用方法
|
BR112022001192A2
(pt)
|
2019-07-23 |
2022-03-15 |
Translate Bio Inc |
Composições estáveis de nanopartículas lipídicas carregadas com mrna e processos de produção
|
JP2022543773A
(ja)
|
2019-07-31 |
2022-10-14 |
モデルナティエックス インコーポレイテッド |
免疫細胞へのrna干渉剤の送達のための組成物及び方法
|
WO2021022108A2
(en)
|
2019-08-01 |
2021-02-04 |
Alnylam Pharmaceuticals, Inc. |
CARBOXYPEPTIDASE B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
WO2021022109A1
(en)
|
2019-08-01 |
2021-02-04 |
Alnylam Pharmaceuticals, Inc. |
SERPIN FAMILY F MEMBER 2 (SERPINF2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
CA3150061A1
(en)
|
2019-08-07 |
2021-02-11 |
Modernatx, Inc. |
Compositions and methods for enhanced delivery of agents
|
WO2021030522A1
(en)
|
2019-08-13 |
2021-02-18 |
Alnylam Pharmaceuticals, Inc. |
SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
ES2918001A2
(es)
|
2019-08-14 |
2022-07-13 |
Acuitas Therapeutics Inc |
Nanoparticulas lipidicas mejoradas para el suministro de acidos nucleicos
|
WO2021028439A1
(en)
|
2019-08-14 |
2021-02-18 |
Curevac Ag |
Rna combinations and compositions with decreased immunostimulatory properties
|
CN116782876A
(zh)
|
2019-08-16 |
2023-09-19 |
瑞泽恩制药公司 |
高浓度抗c5制剂
|
CN114929205A
(zh)
|
2019-09-06 |
2022-08-19 |
世代生物公司 |
包括末端封闭式dna和可切割脂质的脂质纳米颗粒组合物及其使用方法
|
JP2022548304A
(ja)
|
2019-09-19 |
2022-11-17 |
モデルナティエックス インコーポレイテッド |
治療薬の細胞内送達のための分岐状尾部脂質化合物及び組成物
|
CA3155003A1
(en)
|
2019-09-20 |
2021-03-25 |
Translate Bio, Inc. |
Mrna encoding engineered cftr
|
AU2020349991A1
(en)
|
2019-09-20 |
2022-04-07 |
Ractigen Therapeutics |
Nucleic acid molecule for treating immune thrombocytopenia and application thereof
|
US11987791B2
(en)
|
2019-09-23 |
2024-05-21 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating hepatocyte nuclear factor 4-alpha (HNF4α) gene expression
|
CN114391040A
(zh)
|
2019-09-23 |
2022-04-22 |
欧米茄治疗公司 |
用于调节载脂蛋白b(apob)基因表达的组合物和方法
|
EP4045062A1
(en)
|
2019-10-14 |
2022-08-24 |
Astrazeneca AB |
Modulators of pnpla3 expression
|
EP4045076A1
(en)
|
2019-10-15 |
2022-08-24 |
ModernaTX, Inc. |
Mrnas encoding granulocyte-macrophage colony stimulating factor for treating parkinson's disease
|
EP4045652A1
(en)
|
2019-10-18 |
2022-08-24 |
Alnylam Pharmaceuticals, Inc. |
Solute carrier family member irna compositions and methods of use thereof
|
CN115279418A
(zh)
|
2019-10-21 |
2022-11-01 |
川斯勒佰尔公司 |
信使rna的组合物、方法和用途
|
AU2020369515A1
(en)
|
2019-10-22 |
2022-04-21 |
Alnylam Pharmaceuticals, Inc. |
Complement component C3 iRNA compositions and methods of use thereof
|
CN111004738B
(zh)
*
|
2019-10-23 |
2021-09-21 |
上海市第十人民医院 |
一株具核梭杆菌多形亚种分离株及其应用
|
CN111205994B
(zh)
*
|
2019-10-23 |
2021-09-21 |
上海市第十人民医院 |
一株具核梭杆菌动物亚种菌株及其应用
|
CN110903998B
(zh)
*
|
2019-10-23 |
2021-09-21 |
上海市第十人民医院 |
一株肠道分离的具核梭杆菌文氏亚种菌株及其应用
|
JP2022553377A
(ja)
|
2019-10-25 |
2022-12-22 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
C5関連疾患の治療または予防のための投与レジメン
|
TW202132567A
(zh)
|
2019-11-01 |
2021-09-01 |
美商阿尼拉製藥公司 |
亨汀頓蛋白(HTT)iRNA劑組成物及其使用方法
|
KR20220115946A
(ko)
|
2019-11-13 |
2022-08-19 |
알닐람 파마슈티칼스 인코포레이티드 |
안지오텐시노겐 (agt) 관련 장애를 치료하기 위한 방법 및 조성물
|
CN114728016A
(zh)
|
2019-11-15 |
2022-07-08 |
富士胶片株式会社 |
脂质组合物
|
WO2021102373A1
(en)
|
2019-11-22 |
2021-05-27 |
Alnylam Pharmaceuticals, Inc. |
Ataxin3 (atxn3) rnai agent compositions and methods of use thereof
|
JPWO2021117769A1
(zh)
*
|
2019-12-10 |
2021-06-17 |
|
|
WO2021117770A1
(ja)
*
|
2019-12-10 |
2021-06-17 |
富士フイルム株式会社 |
医薬組成物及び処置剤
|
AU2020402885A1
(en)
|
2019-12-13 |
2022-06-16 |
Alnylam Pharmaceuticals, Inc. |
Human chromosome 9 open reading frame 72 (C9orf72) iRNA agent compositions and methods of use thereof
|
WO2021126734A1
(en)
|
2019-12-16 |
2021-06-24 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
BR112022012085A2
(pt)
|
2019-12-20 |
2022-08-30 |
Translate Bio Inc |
Adminstração retal de rna mensageiro
|
CN115461042A
(zh)
|
2019-12-20 |
2022-12-09 |
翻译生物公司 |
制备负载mrna的脂质纳米颗粒的改进方法
|
KR20220121246A
(ko)
|
2019-12-20 |
2022-08-31 |
큐어백 아게 |
핵산 전달용 신규한 지질 나노입자
|
CN110974954B
(zh)
*
|
2019-12-24 |
2021-03-16 |
珠海丽凡达生物技术有限公司 |
一种用于增强核酸疫苗免疫效果的脂质纳米颗粒及其制备方法
|
WO2021142245A1
(en)
|
2020-01-10 |
2021-07-15 |
Translate Bio, Inc. |
Compounds, pharmaceutical compositions and methods for modulating expression of muc5b in lung cells and tissues
|
WO2021142280A1
(en)
|
2020-01-10 |
2021-07-15 |
Modernatx, Inc. |
Methods of making tolerogenic dendritic cells
|
AU2021207504A1
(en)
|
2020-01-15 |
2022-08-04 |
Dicerna Pharmaceuticals, Inc. |
4'-O-methylene phosphonate nucleic acids and analogues thereof
|
WO2021154941A1
(en)
|
2020-01-31 |
2021-08-05 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
|
US20230285297A1
(en)
|
2020-01-31 |
2023-09-14 |
Modernatx, Inc. |
Methods of preparing lipid nanoparticles
|
WO2021156267A1
(en)
|
2020-02-04 |
2021-08-12 |
Curevac Ag |
Coronavirus vaccine
|
WO2021163066A1
(en)
|
2020-02-10 |
2021-08-19 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing vegf-a expression
|
WO2021167841A1
(en)
|
2020-02-18 |
2021-08-26 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
|
CN115427021A
(zh)
|
2020-02-25 |
2022-12-02 |
翻译生物公司 |
制备负载mrna的脂质纳米颗粒的改进方法
|
BR112022016238A2
(pt)
|
2020-02-28 |
2022-10-11 |
Ionis Pharmaceuticals Inc |
Compostos e métodos para modular smn2
|
KR20230011913A
(ko)
*
|
2020-03-04 |
2023-01-25 |
버브 테라퓨틱스, 인크. |
표적화된 rna 전달을 위한 조성물 및 방법
|
EP4114947A1
(en)
|
2020-03-05 |
2023-01-11 |
Alnylam Pharmaceuticals, Inc. |
Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
|
CA3174725A1
(en)
|
2020-03-06 |
2021-09-10 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk) irna compositions and methods of use thereof
|
JP2023517644A
(ja)
|
2020-03-09 |
2023-04-26 |
アークトゥラス・セラピューティクス・インコーポレイテッド |
コロナウイルスワクチン組成物及び方法
|
JP2023517326A
(ja)
|
2020-03-11 |
2023-04-25 |
オメガ セラピューティクス, インコーポレイテッド |
フォークヘッドボックスp3(foxp3)遺伝子発現をモジュレートするための組成物および方法
|
US20230138409A1
(en)
|
2020-03-24 |
2023-05-04 |
Generation Bio Co. |
Non-viral dna vectors and uses thereof for expressing factor ix therapeutics
|
CA3172591A1
(en)
|
2020-03-24 |
2021-09-30 |
Douglas Anthony KERR |
Non-viral dna vectors and uses thereof for expressing gaucher therapeutics
|
TW202204615A
(zh)
|
2020-03-26 |
2022-02-01 |
美商阿尼拉製藥公司 |
冠狀病毒iRNA組成物及其使用方法
|
JP2023520506A
(ja)
|
2020-04-01 |
2023-05-17 |
ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド |
Sars-cov-2に対する多層rnaナノ粒子ワクチン
|
KR20230008729A
(ko)
|
2020-04-06 |
2023-01-16 |
알닐람 파마슈티칼스 인코포레이티드 |
Myoc 발현을 사일런싱하기 위한 조성물 및 방법
|
WO2021206917A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
EP4133077A1
(en)
|
2020-04-07 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
|
CA3179678A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing scn9a expression
|
BR112022021813A2
(pt)
|
2020-04-27 |
2023-01-17 |
Alnylam Pharmaceuticals Inc |
Composições de agente de apolipoproteína e (apoe) irna e métodos de uso das mesmas
|
JP2023523790A
(ja)
|
2020-04-30 |
2023-06-07 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
補体因子B(CFB)iRNA組成物およびその使用方法
|
CA3177940A1
(en)
|
2020-05-07 |
2021-11-11 |
Anusha DIAS |
Optimized nucleotide sequences encoding sars-cov-2 antigens
|
EP4146342A1
(en)
|
2020-05-07 |
2023-03-15 |
Translate Bio, Inc. |
Improved compositions for cftr mrna therapy
|
EP4146680A1
(en)
|
2020-05-07 |
2023-03-15 |
Translate Bio, Inc. |
Composition and methods for treatment of primary ciliary dyskinesia
|
JP2023526059A
(ja)
|
2020-05-14 |
2023-06-20 |
モダーナティエックス・インコーポレイテッド |
mRNA治療薬及びエフェクター分子を含むLNP組成物
|
WO2021231697A1
(en)
|
2020-05-14 |
2021-11-18 |
Translate Bio, Inc. |
Peg lipidoid compounds
|
CA3183399A1
(en)
|
2020-05-15 |
2021-11-18 |
Translate Bio, Inc. |
Lipid nanoparticle formulations for mrna delivery
|
EP4150076A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
|
WO2021231698A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
|
EP4150086A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
|
WO2021231691A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of retinoschisin 1 (rsi)
|
EP4150077A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
|
WO2021231679A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
|
CA3162416C
(en)
|
2020-05-15 |
2023-07-04 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
|
EP4150090A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of otoferlin (otof)
|
BR112022023352A2
(pt)
|
2020-05-18 |
2023-05-02 |
Max Biology Co Ltd |
Composições, método para fornecer um agente bioativo, preparar uma pluralidade de partículas compósitas, tratar doença do olho seco e tratar uma doença ou afecção e método de uso recreativo
|
AU2021275213A1
(en)
|
2020-05-20 |
2023-02-02 |
Flagship Pioneering Innovations Vi, Llc |
Immunogenic compositions and uses thereof
|
JP2023526422A
(ja)
|
2020-05-20 |
2023-06-21 |
フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー |
コロナウイルス抗原組成物及びそれらの使用
|
US20230233474A1
(en)
|
2020-05-28 |
2023-07-27 |
Modernatx, Inc. |
Use of mrnas encoding ox40l, il-23 and il-36gamma for treating cancer
|
MX2022015132A
(es)
|
2020-05-29 |
2023-03-08 |
CureVac SE |
Vacunas combinadas a base de acidos nucleicos.
|
CN116018405A
(zh)
|
2020-05-29 |
2023-04-25 |
旗舰先锋创新Vi有限责任公司 |
Trem组合物及其相关方法
|
AU2021281453A1
(en)
|
2020-05-29 |
2022-11-17 |
Flagship Pioneering Innovations Vi, Llc. |
Trem compositions and methods relating thereto
|
EP4157217A1
(en)
|
2020-06-01 |
2023-04-05 |
Modernatx, Inc. |
Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof
|
EP4158005A1
(en)
|
2020-06-01 |
2023-04-05 |
ModernaTX, Inc. |
Phenylalanine hydroxylase variants and uses thereof
|
US11408000B2
(en)
|
2020-06-03 |
2022-08-09 |
Triplet Therapeutics, Inc. |
Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity
|
EP4162050A1
(en)
|
2020-06-09 |
2023-04-12 |
Alnylam Pharmaceuticals, Inc. |
Rnai compositions and methods of use thereof for delivery by inhalation
|
IL299063A
(en)
|
2020-06-18 |
2023-02-01 |
Alnylam Pharmaceuticals Inc |
Xanthine dehydrogenase (xdh) RNA compositions and methods of using them
|
AU2021297248A1
(en)
|
2020-06-23 |
2023-02-02 |
Modernatx, Inc. |
LNP compositions comprising mRNA therapeutics with extended half-life
|
WO2022006527A1
(en)
|
2020-07-02 |
2022-01-06 |
Maritime Therapeutics, Inc. |
Compositions and methods for reverse gene therapy
|
KR20230050328A
(ko)
|
2020-07-08 |
2023-04-14 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
Hbv에 대한 rna 레플리콘 백신
|
WO2022011262A1
(en)
|
2020-07-10 |
2022-01-13 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for treating epilepsy
|
EP4182297A1
(en)
|
2020-07-16 |
2023-05-24 |
Acuitas Therapeutics, Inc. |
Cationic lipids for use in lipid nanoparticles
|
CN116171326A
(zh)
|
2020-07-17 |
2023-05-26 |
绿光生物科技股份有限公司 |
用于基因病症的核酸疗法
|
WO2022023284A1
(en)
|
2020-07-27 |
2022-02-03 |
Anjarium Biosciences Ag |
Compositions of dna molecules, methods of making therefor, and methods of use thereof
|
CA3170741A1
(en)
|
2020-07-31 |
2022-02-03 |
Curevac Ag |
Nucleic acid encoded antibody mixtures
|
KR20230061389A
(ko)
|
2020-08-04 |
2023-05-08 |
다이서나 파마수이티컬, 인크. |
올리고뉴클레오티드의 전신 전달
|
CA3190790A1
(en)
|
2020-08-06 |
2022-02-10 |
Modernatx, Inc. |
Methods of preparing lipid nanoparticles
|
EP4157344A2
(en)
|
2020-08-31 |
2023-04-05 |
CureVac SE |
Multivalent nucleic acid based coronavirus vaccines
|
CN116157148A
(zh)
|
2020-09-03 |
2023-05-23 |
旗舰创业创新第六有限责任公司 |
免疫原性组合物及其用途
|
JPWO2022054955A1
(zh)
|
2020-09-14 |
2022-03-17 |
|
|
JP2023542944A
(ja)
|
2020-09-23 |
2023-10-12 |
トランスレイト バイオ, インコーポレイテッド |
ピペラジンベースのカチオン性脂質
|
US20230357140A1
(en)
|
2020-09-23 |
2023-11-09 |
Translate Bio, Inc. |
Tes-based cationic lipids
|
WO2022066847A1
(en)
|
2020-09-24 |
2022-03-31 |
Alnylam Pharmaceuticals, Inc. |
Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
|
KR20230086663A
(ko)
*
|
2020-09-25 |
2023-06-15 |
디엔에이알엑스 |
대상체에서 생체분자를 발현하기 위한 시스템 및 방법
|
TW202229552A
(zh)
|
2020-10-05 |
2022-08-01 |
美商艾拉倫製藥股份有限公司 |
G蛋白-偶合受體75(GPR75)iRNA組成物及其使用方法
|
AU2021358490A1
(en)
|
2020-10-05 |
2023-06-01 |
Max Biology Co. Ltd. |
Cannabinoid-containing compositions and use for treating and preventing diseases
|
JP2023544197A
(ja)
|
2020-10-06 |
2023-10-20 |
トランスレイト バイオ, インコーポレイテッド |
脂質ナノ粒子の改善された方法および製剤
|
US20230365995A1
(en)
|
2020-10-07 |
2023-11-16 |
Precision Biosciences, Inc. |
Lipid nanoparticle compositions
|
JP2023545128A
(ja)
|
2020-10-12 |
2023-10-26 |
トランスレイト バイオ, インコーポレイテッド |
mRNA搭載脂質ナノ粒子を製造する改善された方法
|
WO2022081548A1
(en)
|
2020-10-12 |
2022-04-21 |
Translate Bio, Inc. |
Improved process of preparing ice-based lipid nanoparticles
|
CA3198823A1
(en)
|
2020-10-21 |
2022-04-28 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating primary hyperoxaluria
|
EP4232582A1
(en)
|
2020-10-23 |
2023-08-30 |
Alnylam Pharmaceuticals, Inc. |
Mucin 5b (muc5b) irna compositions and methods of use thereof
|
EP4240326A1
(en)
|
2020-11-09 |
2023-09-13 |
Translate Bio, Inc. |
Improved compositions for delivery of codon-optimized mrna
|
AU2021380809A1
(en)
|
2020-11-13 |
2023-06-22 |
Alnylam Pharmaceuticals, Inc. |
COAGULATION FACTOR V (F5) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
CA3199784A1
(en)
|
2020-11-13 |
2022-05-19 |
Modernatx, Inc. |
Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
|
TW202227101A
(zh)
|
2020-11-18 |
2022-07-16 |
美商Ionis製藥公司 |
用於調節血管收縮素原表現之化合物及方法
|
US20220287966A1
(en)
|
2020-11-25 |
2022-09-15 |
Translate Bio, Inc. |
Stable Liquid Lipid Nanoparticle Formulations
|
WO2022112855A1
(en)
|
2020-11-27 |
2022-06-02 |
Guangzhou Ribobio Co., Ltd |
Lipid compound and the composition thereof
|
JP7419542B2
(ja)
|
2020-11-27 |
2024-01-22 |
グアンジョウ リボビオ カンパニー リミテッド |
脂質化合物及びその組成物
|
WO2022110099A1
(en)
|
2020-11-30 |
2022-06-02 |
Guangzhou Argorna Biopharmaceuticals Co., Ltd. |
Coronavirus vaccines and uses thereof
|
CA3201452A1
(en)
|
2020-12-01 |
2022-06-09 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
|
WO2022125490A1
(en)
|
2020-12-08 |
2022-06-16 |
Alnylam Pharmaceuticals, Inc. |
Coagulation factor x (f10) irna compositions and methods of use thereof
|
GB2603454A
(en)
|
2020-12-09 |
2022-08-10 |
Ucl Business Ltd |
Novel therapeutics for the treatment of neurodegenerative disorders
|
CA3171051A1
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
|
WO2022137133A1
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Rna vaccine against sars-cov-2 variants
|
KR20230135585A
(ko)
|
2020-12-23 |
2023-09-25 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
변형된 trem의 조성물 및 이의 용도
|
WO2022146654A1
(en)
|
2020-12-28 |
2022-07-07 |
Janssen Pharmaceuticals, Inc. |
Transcription activator-like effector nucleases (talens) targeting hbv
|
EP4274896A1
(en)
|
2021-01-05 |
2023-11-15 |
Alnylam Pharmaceuticals, Inc. |
Complement component 9 (c9) irna compositions and methods of use thereof
|
EP4277929A1
(en)
|
2021-01-14 |
2023-11-22 |
Translate Bio, Inc. |
Methods and compositions for delivering mrna coded antibodies
|
WO2022162027A2
(en)
|
2021-01-27 |
2022-08-04 |
Curevac Ag |
Method of reducing the immunostimulatory properties of in vitro transcribed rna
|
JPWO2022168884A1
(zh)
|
2021-02-04 |
2022-08-11 |
|
|
US20240123076A1
(en)
|
2021-02-08 |
2024-04-18 |
The Board Of Regents Of The University Of Texas System |
Unsaturated dendrimers compositions, related formulations, and methods of use thereof
|
KR20230146048A
(ko)
|
2021-02-12 |
2023-10-18 |
알닐람 파마슈티칼스 인코포레이티드 |
슈퍼옥사이드 디스뮤타제 1(sod1) irna 조성물 및 슈퍼옥사이드 디스뮤타제 1- (sod1-) 관련 신경퇴행성 질환을 치료하거나 예방하기 위한 이의 사용 방법
|
CA3210878A1
(en)
|
2021-02-12 |
2022-08-18 |
Modernatx, Inc. |
Lnp compositions comprising payloads for in vivo therapy
|
US11524023B2
(en)
|
2021-02-19 |
2022-12-13 |
Modernatx, Inc. |
Lipid nanoparticle compositions and methods of formulating the same
|
EP4298220A1
(en)
|
2021-02-25 |
2024-01-03 |
Alnylam Pharmaceuticals, Inc. |
Prion protein (prnp) irna compositions and methods of use thereof
|
JP2024515423A
(ja)
|
2021-02-26 |
2024-04-10 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
ケトヘキソキナーゼ(KHK)iRNA組成物およびその使用方法
|
IL305353A
(en)
|
2021-02-26 |
2023-10-01 |
Ethris Gmbh |
Spray formulations for the administration of acid bases
|
CA3212128A1
(en)
|
2021-03-04 |
2022-09-09 |
Alnylam Pharmaceuticals, Inc. |
Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
|
EP4305169A1
(en)
|
2021-03-12 |
2024-01-17 |
Alnylam Pharmaceuticals, Inc. |
Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
|
WO2022204380A1
(en)
|
2021-03-24 |
2022-09-29 |
Modernatx, Inc. |
Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof
|
WO2022204369A1
(en)
|
2021-03-24 |
2022-09-29 |
Modernatx, Inc. |
Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
|
WO2022204390A1
(en)
|
2021-03-24 |
2022-09-29 |
Modernatx, Inc. |
Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof
|
WO2022204371A1
(en)
|
2021-03-24 |
2022-09-29 |
Modernatx, Inc. |
Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof
|
WO2022204370A1
(en)
|
2021-03-24 |
2022-09-29 |
Modernatx, Inc. |
Lipid nanoparticles and polynucleotides encoding ornithine transcarbamylase for the treatment of ornithine transcarbamylase deficiency
|
WO2022204549A1
(en)
|
2021-03-25 |
2022-09-29 |
Translate Bio, Inc. |
Optimized nucleotide sequences encoding the extracellular domain of human ace2 protein or a portion thereof
|
CN117377491A
(zh)
|
2021-03-26 |
2024-01-09 |
葛兰素史克生物有限公司 |
免疫原性组合物
|
US20240175033A1
(en)
|
2021-03-26 |
2024-05-30 |
Mina Therapeutics Limited |
TMEM173 saRNA Compositions and Methods of Use
|
KR20230162024A
(ko)
|
2021-03-29 |
2023-11-28 |
알닐람 파마슈티칼스 인코포레이티드 |
헌팅틴(HTT) iRNA 제제 조성물 및 이의 사용 방법
|
WO2022207862A2
(en)
|
2021-03-31 |
2022-10-06 |
Curevac Ag |
Syringes containing pharmaceutical compositions comprising rna
|
EP4313109A1
(en)
|
2021-03-31 |
2024-02-07 |
Flagship Pioneering Innovations V, Inc. |
Thanotransmission polypeptides and their use in treating cancer
|
JP2024512780A
(ja)
|
2021-04-01 |
2024-03-19 |
モデルナティエックス インコーポレイテッド |
多価rna組成物中のrna種の識別及び比率決定のための方法
|
WO2022212153A1
(en)
|
2021-04-01 |
2022-10-06 |
Alnylam Pharmaceuticals, Inc. |
Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof
|
TW202309002A
(zh)
|
2021-04-15 |
2023-03-01 |
美商轉譯生技公司 |
基於「古德」緩衝液的陽離子脂質
|
WO2022225918A1
(en)
|
2021-04-19 |
2022-10-27 |
Translate Bio, Inc. |
Improved compositions for delivery of mrna
|
CA3214538A1
(en)
|
2021-04-20 |
2022-10-27 |
Joel DE BEER |
Compositions of dna molecules encoding amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase, methods of making thereof, and methods of use thereof
|
WO2022226318A1
(en)
|
2021-04-23 |
2022-10-27 |
Modernatx, Inc. |
Isoquinoline-stabilized lipid nanoparticle formulations
|
WO2022226277A1
(en)
|
2021-04-23 |
2022-10-27 |
Modernatx, Inc. |
Stabilized formulations
|
IL307926A
(en)
|
2021-04-26 |
2023-12-01 |
Alnylam Pharmaceuticals Inc |
Transmembrane assemblies, serine 6 ((TMPRSS6 IRNA) and methods of using them
|
WO2022232286A1
(en)
|
2021-04-27 |
2022-11-03 |
Generation Bio Co. |
Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
|
KR20240011714A
(ko)
|
2021-04-27 |
2024-01-26 |
제너레이션 바이오 컴퍼니 |
치료용 항체를 발현하는 비바이러스성 dna 벡터 및 이의 용도
|
JP2024519293A
(ja)
|
2021-04-29 |
2024-05-10 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
シグナル伝達兼転写活性化因子6(STAT6)iRNA組成物およびその使用方法
|
WO2022232585A1
(en)
|
2021-04-29 |
2022-11-03 |
Modernatx, Inc. |
Lyophilization methods for preparing lipid formulated therapeutics
|
WO2022233880A1
(en)
|
2021-05-03 |
2022-11-10 |
Curevac Ag |
Improved nucleic acid sequence for cell type specific expression
|
EP4337177A1
(en)
|
2021-05-11 |
2024-03-20 |
Modernatx, Inc. |
Non-viral delivery of dna for prolonged polypeptide expression in vivo
|
WO2022245583A1
(en)
|
2021-05-18 |
2022-11-24 |
Alnylam Pharmaceuticals, Inc. |
Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof
|
WO2022246020A1
(en)
|
2021-05-19 |
2022-11-24 |
Modernatx, Inc. |
Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
|
EP4341405A1
(en)
|
2021-05-20 |
2024-03-27 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
CN113546180A
(zh)
*
|
2021-05-25 |
2021-10-26 |
重庆医科大学 |
一种具有心肌靶向性的基因递送载体及其制备方法
|
WO2022246571A1
(en)
*
|
2021-05-28 |
2022-12-01 |
Nanovation Therapeutics Inc. |
Mc3-type lipids and use thereof in the preparation of lipid nanoparticles
|
WO2022256283A2
(en)
|
2021-06-01 |
2022-12-08 |
Korro Bio, Inc. |
Methods for restoring protein function using adar
|
TW202317762A
(zh)
|
2021-06-02 |
2023-05-01 |
美商艾拉倫製藥股份有限公司 |
含有類PATATIN磷脂酶結構域3(PNPLA3)的iRNA組成物及其使用方法
|
BR112023025224A2
(pt)
|
2021-06-04 |
2024-02-27 |
Alnylam Pharmaceuticals Inc |
Quadro de leitura aberto 72 do cromossomo humano 9 (c9orf72) composições de agente de irna e métodos de uso dos mesmos
|
AR126070A1
(es)
|
2021-06-08 |
2023-09-06 |
Alnylam Pharmaceuticals Inc |
Composiciones y métodos para tratar o prevenir la enfermedad de stargardt y/o trastornos asociados con la proteína transportadora de retinol 4 (rbp4)
|
WO2022260772A1
(en)
*
|
2021-06-09 |
2022-12-15 |
Carnegie Mellon University |
Lipid nanoparticle formulations for gastrointestinal delivery
|
EP4355882A2
(en)
|
2021-06-15 |
2024-04-24 |
Modernatx, Inc. |
Engineered polynucleotides for cell-type or microenvironment-specific expression
|
WO2022271776A1
(en)
|
2021-06-22 |
2022-12-29 |
Modernatx, Inc. |
Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
|
EP4360624A1
(en)
*
|
2021-06-24 |
2024-05-01 |
Therna Therapeutics |
Lipid nanoparticles and method for preparing same
|
KR102516680B1
(ko)
*
|
2021-06-24 |
2023-04-03 |
주식회사 테르나테라퓨틱스 |
지질 나노 입자 및 그 제조방법
|
US20230194709A9
(en)
|
2021-06-29 |
2023-06-22 |
Seagate Technology Llc |
Range information detection using coherent pulse sets with selected waveform characteristics
|
WO2023278410A1
(en)
|
2021-06-29 |
2023-01-05 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
KR20240026203A
(ko)
|
2021-06-30 |
2024-02-27 |
알닐람 파마슈티칼스 인코포레이티드 |
안지오텐시노겐(agt)-관련 장애를 치료하는 방법 및 조성물
|
WO2023278754A1
(en)
|
2021-07-01 |
2023-01-05 |
Translate Bio, Inc. |
Compositions for delivery of mrna
|
WO2023278811A1
(en)
|
2021-07-01 |
2023-01-05 |
Indapta Therapeutics, Inc. |
Engineered natural killer (nk) cells and related methods
|
EP4367242A2
(en)
|
2021-07-07 |
2024-05-15 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression
|
WO2023283403A2
(en)
|
2021-07-09 |
2023-01-12 |
Alnylam Pharmaceuticals, Inc. |
Bis-rnai compounds for cns delivery
|
WO2023287751A1
(en)
|
2021-07-12 |
2023-01-19 |
Modernatx, Inc. |
Polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits for the treatment of propionic acidemia
|
WO2023003922A1
(en)
|
2021-07-21 |
2023-01-26 |
Alnylam Pharmaceuticals, Inc. |
Metabolic disorder-associated target gene irna compositions and methods of use thereof
|
AU2022316139A1
(en)
|
2021-07-23 |
2024-01-18 |
Alnylam Pharmaceuticals, Inc. |
Beta-catenin (ctnnb1) irna compositions and methods of use thereof
|
EP4377457A1
(en)
|
2021-07-26 |
2024-06-05 |
Flagship Pioneering Innovations VI, LLC |
Trem compositions and uses thereof
|
WO2023009499A1
(en)
|
2021-07-27 |
2023-02-02 |
Modernatx, Inc. |
Polynucleotides encoding glucose-6-phosphatase for the treatment of glycogen storage disease type 1a (gsd1a)
|
EP4379054A1
(en)
|
2021-07-27 |
2024-06-05 |
Stand Therapeutics Co., Ltd. |
Peptide tag and nucleic acid encoding same
|
EP4377458A1
(en)
|
2021-07-29 |
2024-06-05 |
Alnylam Pharmaceuticals, Inc. |
3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof
|
CA3171750A1
(en)
|
2021-07-30 |
2023-02-02 |
Tim SONNTAG |
Mrnas for treatment or prophylaxis of liver diseases
|
CA3227103A1
(en)
|
2021-07-30 |
2023-02-02 |
Matthew P. GEMBERLING |
Compositions and methods for modulating expression of frataxin (fxn)
|
WO2023010135A1
(en)
|
2021-07-30 |
2023-02-02 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
|
WO2023014649A1
(en)
|
2021-08-02 |
2023-02-09 |
Modernatx, Inc. |
Extraction-less reverse phase (rp) chromatography of mrna encapsulated in lipid nanoparticles for mrna purity assessment
|
CN117795074A
(zh)
|
2021-08-03 |
2024-03-29 |
阿尔尼拉姆医药品有限公司 |
转甲状腺素蛋白(TTR)iRNA组合物和其使用方法
|
WO2023015261A1
(en)
|
2021-08-04 |
2023-02-09 |
Modernatx, Inc. |
Mrnas encoding chimeric metabolic reprogramming polypeptides and uses thereof
|
WO2023014765A1
(en)
|
2021-08-04 |
2023-02-09 |
Alnylam Pharmaceuticals, Inc. |
iRNA COMPOSITIONS AND METHODS FOR SILENCING ANGIOTENSINOGEN (AGT)
|
WO2023014974A1
(en)
|
2021-08-06 |
2023-02-09 |
University Of Iowa Research Foundation |
Double stranded mrna vaccines
|
WO2023019181A1
(en)
|
2021-08-11 |
2023-02-16 |
Modernatx, Inc. |
Sars-cov-2 lipid nanoparticle vaccine formulations
|
WO2023018773A1
(en)
|
2021-08-11 |
2023-02-16 |
Modernatx, Inc. |
Lipid nanoparticle formulations and methods of synthesis thereof
|
TW202334413A
(zh)
|
2021-08-13 |
2023-09-01 |
美商艾拉倫製藥股份有限公司 |
第十二因子(F12)iRNA組成物及其使用方法
|
IL309505A
(en)
|
2021-09-03 |
2024-02-01 |
CureVac SE |
Lipid nanoparticles for nucleic acid delivery
|
AU2022336664A1
(en)
|
2021-09-03 |
2024-01-18 |
CureVac SE |
Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
|
AU2022337090A1
(en)
|
2021-09-03 |
2024-02-15 |
Glaxosmithkline Biologicals Sa |
Substitution of nucleotide bases in self-amplifying messenger ribonucleic acids
|
AR127073A1
(es)
|
2021-09-17 |
2023-12-13 |
Flagship Pioneering Innovations Vi Llc |
Composiciones y métodos para producir polirribonucleótidos circulares
|
WO2023044370A2
(en)
|
2021-09-17 |
2023-03-23 |
Alnylam Pharmaceuticals, Inc. |
Irna compositions and methods for silencing complement component 3 (c3)
|
CA3232420A1
(en)
|
2021-09-20 |
2023-03-23 |
Alnylam Pharmaceuticals, Inc. |
Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
|
WO2023056044A1
(en)
|
2021-10-01 |
2023-04-06 |
Modernatx, Inc. |
Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease
|
WO2023056401A1
(en)
|
2021-10-01 |
2023-04-06 |
Modernatx, Inc. |
Rna formulations for high volume distribution, and methods of using the same for treating a disease or condition caused by or associated with human cytomegalovirus
|
WO2023064469A1
(en)
|
2021-10-13 |
2023-04-20 |
Modernatx, Inc. |
Compositions of mrna-encoded il15 fusion proteins and methods of use thereof
|
AU2022364838A1
(en)
|
2021-10-15 |
2024-04-11 |
Alnylam Pharmaceuticals, Inc. |
Extra-hepatic delivery irna compositions and methods of use thereof
|
CA3235625A1
(en)
|
2021-10-18 |
2023-04-27 |
Flagship Pioneering Innovations Vi, Llc |
Compositions and methods for purifying polyribonucleotides
|
WO2023069895A1
(en)
|
2021-10-18 |
2023-04-27 |
Modernatx, Inc. |
Markerless dna production
|
CA3234835A1
(en)
|
2021-10-22 |
2023-04-27 |
Korro Bio, Inc. |
Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
|
WO2023073534A1
(en)
|
2021-10-26 |
2023-05-04 |
Astrazeneca Ab |
Novel lipids for delivery of nucleic acid segments
|
WO2023073228A1
(en)
|
2021-10-29 |
2023-05-04 |
CureVac SE |
Improved circular rna for expressing therapeutic proteins
|
WO2023076450A2
(en)
|
2021-10-29 |
2023-05-04 |
Alnylam Pharmaceuticals, Inc. |
HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
TW202333749A
(zh)
|
2021-10-29 |
2023-09-01 |
美商艾拉倫製藥股份有限公司 |
補體因子b(cfb)irna組成物及其使用方法
|
WO2023077170A1
(en)
|
2021-11-01 |
2023-05-04 |
Modernatx, Inc. |
Polynucleotides encoding integrin beta-6 and methods of use thereof
|
WO2023081526A1
(en)
|
2021-11-08 |
2023-05-11 |
Orna Therapeutics, Inc. |
Lipid nanoparticle compositions for delivering circular polynucleotides
|
KR20230068047A
(ko)
|
2021-11-10 |
2023-05-17 |
주식회사 에스엠엘바이오팜 |
트레할로즈 유도체 및 신규 구조 유지 화합물을 포함하는 핵산 의약품 전달용 지질나노입자의 약학 조성물
|
WO2023086893A1
(en)
|
2021-11-10 |
2023-05-19 |
Translate Bio, Inc. |
Composition and methods for treatment of primary ciliary dyskinesia
|
WO2023092060A1
(en)
|
2021-11-18 |
2023-05-25 |
Cornell University |
Microrna-dependent mrna switches for tissue-specific mrna-based therapies
|
US20230181482A1
(en)
|
2021-11-18 |
2023-06-15 |
Astrazeneca Ab |
Lipids for delivery of nucleic acid segments
|
WO2023092151A1
(en)
*
|
2021-11-22 |
2023-05-25 |
Ohio State Innovation Foundation |
Compositions and methods for the treatment of neurodegenerative disorders
|
WO2023097003A2
(en)
|
2021-11-24 |
2023-06-01 |
Flagship Pioneering Innovations Vi, Llc |
Immunogenic compositions and their uses
|
WO2023096990A1
(en)
|
2021-11-24 |
2023-06-01 |
Flagship Pioneering Innovation Vi, Llc |
Coronavirus immunogen compositions and their uses
|
AU2022397292A1
(en)
|
2021-11-24 |
2024-05-30 |
Flagship Pioneering Innovations Vi, Llc |
Varicella-zoster virus immunogen compositions and their uses
|
WO2023099884A1
(en)
|
2021-12-01 |
2023-06-08 |
Mina Therapeutics Limited |
Pax6 sarna compositions and methods of use
|
WO2023107999A2
(en)
|
2021-12-08 |
2023-06-15 |
Modernatx, Inc. |
Herpes simplex virus mrna vaccines
|
GB202117758D0
(en)
|
2021-12-09 |
2022-01-26 |
Ucl Business Ltd |
Therapeutics for the treatment of neurodegenerative disorders
|
WO2023114307A1
(en)
|
2021-12-15 |
2023-06-22 |
Modernatx, Inc. |
Determination of encapsulation efficiency of lipid nanoparticles
|
WO2023114889A1
(en)
|
2021-12-16 |
2023-06-22 |
Modernatx, Inc. |
Processes for preparing lipid nanoparticles
|
WO2023122745A1
(en)
|
2021-12-22 |
2023-06-29 |
Flagship Pioneering Innovations Vi, Llc |
Compositions and methods for purifying polyribonucleotides
|
WO2023122762A1
(en)
|
2021-12-22 |
2023-06-29 |
Camp4 Therapeutics Corporation |
Modulation of gene transcription using antisense oligonucleotides targeting regulatory rnas
|
TW202342064A
(zh)
|
2021-12-23 |
2023-11-01 |
美商旗艦先鋒創新有限責任公司 |
編碼抗融合多肽之環狀多核糖核苷酸
|
WO2023133595A2
(en)
|
2022-01-10 |
2023-07-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
CN114044741B
(zh)
|
2022-01-13 |
2022-04-15 |
北京悦康科创医药科技股份有限公司 |
一种阳离子脂质化合物、包含其的组合物及用途
|
WO2023135273A2
(en)
|
2022-01-14 |
2023-07-20 |
Anjarium Biosciences Ag |
Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof
|
WO2023135298A1
(en)
|
2022-01-17 |
2023-07-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of inducing cell death of a population of solid tumor cells
|
WO2023141314A2
(en)
|
2022-01-24 |
2023-07-27 |
Alnylam Pharmaceuticals, Inc. |
Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
|
WO2023144193A1
(en)
|
2022-01-25 |
2023-08-03 |
CureVac SE |
Mrnas for treatment of hereditary tyrosinemia type i
|
WO2023147090A1
(en)
|
2022-01-27 |
2023-08-03 |
BioNTech SE |
Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
|
WO2023144330A1
(en)
|
2022-01-28 |
2023-08-03 |
CureVac SE |
Nucleic acid encoded transcription factor inhibitors
|
WO2023150647A1
(en)
|
2022-02-02 |
2023-08-10 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
WO2023152365A1
(en)
|
2022-02-14 |
2023-08-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of the 15-lipoxygenase for the treatment of lymphedema
|
TW202345864A
(zh)
|
2022-02-18 |
2023-12-01 |
美商現代公司 |
編碼檢查點癌症疫苗之mRNA及其用途
|
WO2023161350A1
(en)
|
2022-02-24 |
2023-08-31 |
Io Biotech Aps |
Nucleotide delivery of cancer therapy
|
WO2023170435A1
(en)
|
2022-03-07 |
2023-09-14 |
Mina Therapeutics Limited |
Il10 sarna compositions and methods of use
|
WO2023177655A1
(en)
|
2022-03-14 |
2023-09-21 |
Generation Bio Co. |
Heterologous prime boost vaccine compositions and methods of use
|
TW202345835A
(zh)
|
2022-03-16 |
2023-12-01 |
美商轉譯生技公司 |
非對稱的基於哌嗪之陽離子脂質
|
WO2023177904A1
(en)
|
2022-03-18 |
2023-09-21 |
Modernatx, Inc. |
Sterile filtration of lipid nanoparticles and filtration analysis thereof for biological applications
|
WO2023183909A2
(en)
|
2022-03-25 |
2023-09-28 |
Modernatx, Inc. |
Polynucleotides encoding fanconi anemia, complementation group proteins for the treatment of fanconi anemia
|
WO2023193002A1
(en)
|
2022-04-01 |
2023-10-05 |
Modernatx, Inc. |
Cross mixers for lipid nanoparticle production, and methods of operating the same
|
WO2023196399A1
(en)
|
2022-04-06 |
2023-10-12 |
Modernatx, Inc. |
Lipid nanoparticles and polynucleotides encoding argininosuccinate lyase for the treatment of argininosuccinic aciduria
|
WO2023196988A1
(en)
|
2022-04-07 |
2023-10-12 |
Modernatx, Inc. |
Methods of use of mrnas encoding il-12
|
WO2023196634A2
(en)
|
2022-04-08 |
2023-10-12 |
Flagship Pioneering Innovations Vii, Llc |
Vaccines and related methods
|
WO2023200893A1
(en)
*
|
2022-04-13 |
2023-10-19 |
Oregon State University |
Small molecule enhancers of antisense oligo activity
|
WO2023198857A1
(en)
|
2022-04-13 |
2023-10-19 |
Sanofi |
"good" buffer-based cationic lipids
|
WO2023201296A1
(en)
|
2022-04-15 |
2023-10-19 |
Modernatx, Inc. |
Ribosomal engagement potency assay
|
WO2023212696A1
(en)
|
2022-04-29 |
2023-11-02 |
Modernatx, Inc. |
Lyophilized human cytomegalovirus vaccines
|
WO2023215498A2
(en)
|
2022-05-05 |
2023-11-09 |
Modernatx, Inc. |
Compositions and methods for cd28 antagonism
|
WO2023220083A1
(en)
|
2022-05-09 |
2023-11-16 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and methods of use for treating proliferative disorders
|
WO2023220734A2
(en)
*
|
2022-05-13 |
2023-11-16 |
The Trustees Of The University Of Pennsylvania |
Bisphosphonate lipids, lipid nanoparticle compositions comprising the same, and methods of use thereof for targeted delivery
|
WO2023220729A2
(en)
|
2022-05-13 |
2023-11-16 |
Flagship Pioneering Innovations Vii, Llc |
Double stranded dna compositions and related methods
|
WO2023218420A1
(en)
|
2022-05-13 |
2023-11-16 |
Janssen Pharmaceuticals, Inc. |
Mrna compositions for inducing latent hiv-1 reversal
|
WO2023227608A1
(en)
|
2022-05-25 |
2023-11-30 |
Glaxosmithkline Biologicals Sa |
Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
|
WO2023230601A1
(en)
|
2022-05-27 |
2023-11-30 |
Beam Therapeutics Inc. |
Identification of nanoparticles for preferential tissue or cell targeting
|
WO2023239756A1
(en)
|
2022-06-07 |
2023-12-14 |
Generation Bio Co. |
Lipid nanoparticle compositions and uses thereof
|
WO2023240277A2
(en)
|
2022-06-10 |
2023-12-14 |
Camp4 Therapeutics Corporation |
Methods of modulating progranulin expression using antisense oligonucleotides targeting regulatory rnas
|
CN117263818A
(zh)
*
|
2022-06-14 |
2023-12-22 |
杭州高田生物医药有限公司 |
阳离子脂质化合物及其制备方法和应用
|
WO2023242817A2
(en)
|
2022-06-18 |
2023-12-21 |
Glaxosmithkline Biologicals Sa |
Recombinant rna molecules comprising untranslated regions or segments encoding spike protein from the omicron strain of severe acute respiratory coronavirus-2
|
WO2023250112A1
(en)
|
2022-06-22 |
2023-12-28 |
Flagship Pioneering Innovations Vi, Llc |
Compositions of modified trems and uses thereof
|
WO2023250511A2
(en)
|
2022-06-24 |
2023-12-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression
|
WO2024007020A1
(en)
|
2022-06-30 |
2024-01-04 |
Indapta Therapeutics, Inc. |
Combination of engineered natural killer (nk) cells and antibody therapy and related methods
|
WO2024015881A2
(en)
|
2022-07-12 |
2024-01-18 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for targeted transcriptional activation
|
WO2024015890A1
(en)
|
2022-07-13 |
2024-01-18 |
Modernatx, Inc. |
Norovirus mrna vaccines
|
WO2024023034A1
(en)
|
2022-07-25 |
2024-02-01 |
Institut National de la Santé et de la Recherche Médicale |
Use of apelin for the treatment of lymphedema
|
WO2024026254A1
(en)
|
2022-07-26 |
2024-02-01 |
Modernatx, Inc. |
Engineered polynucleotides for temporal control of expression
|
WO2024026482A1
(en)
|
2022-07-29 |
2024-02-01 |
Modernatx, Inc. |
Lipid nanoparticle compositions comprising surface lipid derivatives and related uses
|
WO2024026475A1
(en)
|
2022-07-29 |
2024-02-01 |
Modernatx, Inc. |
Compositions for delivery to hematopoietic stem and progenitor cells (hspcs) and related uses
|
WO2024026487A1
(en)
|
2022-07-29 |
2024-02-01 |
Modernatx, Inc. |
Lipid nanoparticle compositions comprising phospholipid derivatives and related uses
|
WO2024030369A1
(en)
|
2022-08-01 |
2024-02-08 |
Modernatx, Inc. |
Extraction-less reverse phase (rp) chromatography for mrna purity assessment
|
WO2024030856A2
(en)
|
2022-08-01 |
2024-02-08 |
Flagship Pioneering Innovations Vii, Llc |
Immunomodulatory proteins and related methods
|
WO2024035952A1
(en)
|
2022-08-12 |
2024-02-15 |
Remix Therapeutics Inc. |
Methods and compositions for modulating splicing at alternative splice sites
|
WO2024039776A2
(en)
|
2022-08-18 |
2024-02-22 |
Alnylam Pharmaceuticals, Inc. |
Universal non-targeting sirna compositions and methods of use thereof
|
WO2024040222A1
(en)
|
2022-08-19 |
2024-02-22 |
Generation Bio Co. |
Cleavable closed-ended dna (cedna) and methods of use thereof
|
US20240067968A1
(en)
|
2022-08-19 |
2024-02-29 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for regulation of hepatitis b virus through targeted gene repression
|
WO2024044147A1
(en)
|
2022-08-23 |
2024-02-29 |
Modernatx, Inc. |
Methods for purification of ionizable lipids
|
WO2024042236A1
(en)
|
2022-08-26 |
2024-02-29 |
Ethris Gmbh |
Stable lipid or lipidoid nanoparticle suspensions
|
EP4327829A1
(en)
|
2022-08-26 |
2024-02-28 |
Ethris GmbH |
Stabilization of lipid or lipidoid nanoparticle suspensions
|
WO2024050483A1
(en)
|
2022-08-31 |
2024-03-07 |
Modernatx, Inc. |
Variant strain-based coronavirus vaccines and uses thereof
|
WO2024047247A1
(en)
|
2022-09-02 |
2024-03-07 |
Institut National de la Santé et de la Recherche Médicale |
Base editing approaches for the treatment of amyotrophic lateral sclerosis
|
WO2024059165A1
(en)
|
2022-09-15 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
|
WO2024064642A2
(en)
|
2022-09-19 |
2024-03-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for modulating t cell function
|
WO2024064931A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of liver stage antigens and related methods
|
WO2024063789A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of malaria antigens and related methods
|
WO2024063788A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of malaria antigens and related methods
|
WO2024064934A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of plasmodium csp antigens and related methods
|
WO2024068545A1
(en)
|
2022-09-26 |
2024-04-04 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
WO2024077191A1
(en)
|
2022-10-05 |
2024-04-11 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|
WO2024091918A2
(en)
|
2022-10-25 |
2024-05-02 |
Modernatx, Inc. |
Methods of lipid nanoparticle production in cross-mixers
|
US20240156949A1
(en)
|
2022-10-28 |
2024-05-16 |
Glaxosmithkline Biologicals Sa |
Nucleic Acid Based Vaccine
|
WO2024097639A1
(en)
|
2022-10-31 |
2024-05-10 |
Modernatx, Inc. |
Hsa-binding antibodies and binding proteins and uses thereof
|
WO2024097664A1
(en)
|
2022-10-31 |
2024-05-10 |
Flagship Pioneering Innovations Vi, Llc |
Compositions and methods for purifying polyribonucleotides
|
WO2024097874A1
(en)
|
2022-11-03 |
2024-05-10 |
Modernatx, Inc. |
Chemical stability of mrna
|
WO2024102677A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Circular rna compositions
|
WO2024102762A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
WO2024102730A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and nanoparticle compositions for delivering polynucleotides
|
WO2024102799A1
(en)
|
2022-11-08 |
2024-05-16 |
Flagship Pioneering Innovations Vi, Llc |
Compositions and methods for producing circular polyribonucleotides
|